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ABSTRACT 
Cell surface saccharides are involved in a variety of essential biological events. Fluorescent 
sensors for saccharides can be used for detection, diagnosis, analysis and monitoring of 
pathological processes.  The boronic acid functional group is known to bind strongly and 
reversibly to compounds with diol groups, which are commonly found on saccharides. Sensors 
that have been developed for the purpose of saccharide recognition have shown great potential.  
However, they are very hydrophobic and this lack of essential water-solubility makes them 
useful in biological applications.  The first section of this dissertation details the process of 
developing water-soluble saccharide sensors that change fluorescent properties upon binding to 
saccharides.  
 
The second section of the dissertation focuses on the development of DNA-minor groove 
binders as antiparasitical agents. Parasitical diseases comprise some of the world’s largest 
health problems and yet current medication and treatments for these parasitical diseases are 
often difficult to administer, costly to the patients, and have disruptive side effects.  Worse yet, 
these parasites are developing drug resistance, thus creating an urgent need for new treatments.  
Dicationic molecules constitute a class of antimicrobial drug candidates that possess high 
activity against various parasites. The second section details the development of a series of di-
cationic agents that were then screened in in vitro activities against parasitical species.  
 
INDEX WORDS: Boronolectins, Carbohydrate sensing, Benzo[b]thiophene boronic acid, 
Physiological pH, DNA-minor groove, DNA-binders, HAT, Leishmaniasis, 
Malaria 
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SECTION I 
BORONIC ACID BASED SENSOR FOR CELL SURFACE GLYCOLIPIDS 
1. Introduction 
1.1. The Importance of Cell Surface Glycolipids Sensors 
Mammalian cell surfaces are coated with saccharides. These saccharides, in the forms of 
glycosylated proteins, peptides, and lipids, are characteristic fingerprints of different cell 
types.1-5 These glycosylated biomolecules are involved in a variety of essential biological 
events such as adhesion, blood generation, cancer metastasis, cell-cell communications, and 
viral infection.4, 6 , 7, 8 For example, cell-cell adhesion in the inflammatory processes involves 
lectin-carbohydrate interactions, and neutrophils inflammation was found to be mediated in 
part by the endothelial leukocyte adhesion molecule-1 (ELAM-1). ELAM-1 is part of a selectin 
family of adhesion molecules that contain a lectin motif thought to recognize carbohydrate 
ligands.9 Embryonic development at early stages is known to rely on Lewis X for cell-cell 
adhesion.10  
Virus glycoproteins specifically attach to the sialic acid region on the host cell surface. The 
human influenza virus prefers to bind to sialic acid attached to galactose in α 2, 6 linkage. 
However, the Avian influenza virus, in contrast to the human influenza virus, binds in α 2, 3 
linkages.11-13 HIV infection is mediated by glycoprotein binding with cell surface receptors.14, 
15  
The altered cell-surface protein glycosylation or the expressions of certain glycoproteins have 
been associated with many cancer types.3, 16, 17 Certain cell surface saccharides involved in 
cancer and that are over expressed on cancer cells include sialyl Lewis X (sLex), sialyl Lewis 
A (sLea), Lewis Y (Ley), Lewis X. 18-21 Therefore, artificially designed small molecules, which 
2  
are mimics of proteins that bind to cell surface carbohydrates, could potentially be used for 
diagnosis and therapeutics.   
1.2. Interaction Between Boronic Acid and Carbohydrate Containing Diols 
The first observation reported the ability of boronic and boric acid to bind with diols, resulting 
in the acidity increase of the boric acid solution after the addition of sugars. The comprehensive 
study of phenyl boronic acid and different diols demonstrated that different diols show different 
affinity for the boronic acid group, lowering the acidity of the boron species to different 
levels.22 Boronic acids have found to covalently react with 1,2 or 1,3 diols to form reversible 
five- or six-membered complexes.22 It is important to understand the interaction mechanism 
between diols and boronic acid. The acidity of boronic acid is unlike that of carboxylic acids. 
The acidity relays on the proton release from the boronate species, which forms by reaction 
with water molecules. This is shown in Figure 1.1.  
B(OH)2
B O
O
-B
-B
HO
O
O
OH
OH
R1
R2
+ H2O, - H+
+ H2O, - H+
K eq-trig
-2 H2O
K eq-tet
-2 H2O
R1 R2
HO OH
R1 R2
HO OH
HO
R1
R2
B B-
BD BD-  
Figure 1.1. Binding process between phenylboronic acid and a diol. 
 
 
Boronic acids are Lewis acids and they react with the long pair electrons of an oxygen atom of 
water to form the neutral trigonal form (B) to the anionic tetrahedral form (B-). The same 
3  
mechanism is true for the diol – boronic complex; (BD) is also an acid and can react with water 
to release a proton. 
1.3. Binding Constants Determination 
In order to evaluate the binding interactions between boronic acids and diols, it is essential to 
have sensitive and accurate methods for the determination of their binding constants. The pH 
depression method and the 11B-NMR method were the first two methods commonly used for 
determining binding constants. However, these techniques have drawbacks because of 
insensitivity, the requirement of large samples, and long experiment times. Recent efforts have 
focused on spectroscopic methods, which are highly sensitive, rapid, and require a smaller 
sample.  
1.3.1. pH-Depression Method 
This method is based on the detection of pH changes according to diol boronic acid interaction. 
The diol addition to a boronic acid solution lowers the pH of the solution. The extent of the pH 
lowering effect of a particular diol can be correlated with the “binding constant” between these 
two species.  
1.3.2. 11B-NMR Method 
The other method that has been used is based on the detection of 11B-NMR chemical shift 
differences. The addition of sugar to the boronic acid solution forms the ester complex.  The 
pKa of the boronic acid is lower than the free form. This change results in physical changes on 
the boron atom. The boron atom converts from the neutral trigonal form to the anionic 
tetrahedral form. The 11B-NMR can detect the significant chemical shift differences. Using a 
similar mathematical derivation, as used in pH-depression method, the binding constants of 
4  
boric acid with diols are determined. However, the 11B-NMR method requires high 
concentration of the sensor compound and longer NMR detection for boron atom.23-25  
1.3.3. Spectroscopic Methods 
Because of the low sensitivity and the requirement of large samples, the preferred binding 
determination method has now changed to spectroscopic methods, which are generally more 
sensitive than classical methods.  However, for using spectroscopic applications, the complex 
formation between diols and boronic acids needs to trigger a change in the spectroscopic 
properties of the boronic acid component. These changes can be evaluated depending on the 
esters complex spectroscopic properties such as CD, absorption, and fluorescence. The 
association constant is determined from the plot of spectroscopic intensity change verses 
several of the diol concentrations.  
1.4. Spectroscopic Boronic Acid Compounds  
1.4.1. Photoelectron Transfer (PET) 
The requirement for spectroscopic detection for boronic acid reporter compounds is the boronic 
acid unit has to change the spectroscopic properties upon diol binding. Czarnick et. al. 
determined the binding constant of anthrylboronic acid with D-fructose at physiological pH 
using fluorescence spectroscopy.26  Their fluorescent sensor, 2- anthrylboronic acid, was design 
based on the modulation of an excited state photoelectron transfer (PET) process that is 
responsible for the quenching of fluorescence. The free 2-anthrylboronic acid apparent pKa is 
about 8.8. The addition of fructose lowers the complex apparent pKa to about 5.9. The complex 
is exits in the anionic tetrahedral form at physiological pH. The formation of boronate anion 
quenched the anthracene fluorescence.   
5  
The other mostly used anthracene system was developed by Shinkai et. al. The amino group 
was positioned in a 1,5- relationship with the boron atom. The long pair electrons of nitrogen 
promote B-N bound formation. This system also showed a significant fluorescence intensity 
change by addition of sugars.27, 28 The initial explanation of the fluorescence change 
mechanism was suggested by the modulation of the excited state PET through the formation of 
the B-N bond. It is known that long pair electron on the benzylic amine quenched the 
anthracene fluorescence. 
(HO)2B
N
hv
hv'
OHHO
R2R1
.. N
B
O
O
R2
R1
hv hv
Boronic acid
Weak fluorescence
Boronic ester
Strong fluorescence
H
+
OH
-
E
LUMO
Donor
PET
Fluorophore
HOMO
HOMO
E
HOMO
LUMO
HOMO
DonorFluorophore  
Figure 1.2. Suggested mechanism of an anthracene-based photoinduced electron transfer 
system.  
 
The anthracene boronic acid is weakly fluorescence at free boronic acid formation. Upon 
addition of sugar, the acidity of boron increase. As a result, long pair electrons forms a B-N 
bound. Therefore, the fluorescence quenching long pair electrons is not available to quench the 
anthracene system and fluorescence increase. Wang et.al. suggested a different mechanism for 
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the fluorescent intensity change by hydrolysis mechanism. In this theory, the protonation of 
nitrogen also could responsible for fluorescence change by tie up the long pair electrons. 
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Figure 1.3. The possible mechanisms for the anthracene boronic acid fluorescence intensity 
change. 
  
The detail examination of pH profile of the free boronic acid and the ester complex supported 
the hydrolysis mechanism, Figure 1.3.29, 30 
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1.4.2. Internal Charge Transfer 
The first internal charge transfer based fluorescent boronic acid compounds as a carbohydrate 
sensor introduced by s Shinkai group in 1994.31 The ICT system contains an electron donor 
group and electron acceptor in the same fluorophore. The empty valance orbital on boronic acid 
acts as an electron acceptor in the natural form. Upon addition of sugar, boronic acid group 
turns into its tetrahedral anionic form at certain pH and it is no longer an electron acceptor. 
This physical change of the molecule leads to the spectral changes because of the perturbation 
of charge transfer nature of the excited state and triggers the change of the fluorescence 
spectrum.32 
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Figure 1.4. The possible binding mechanism of ICT based fluorescent boronic acid 
compounds. 
 
 
1.4.3. Alizarin Red S. (ARS) 
Boronic acids compound has been found to be a great tools for carbohydrate recognition. The 
spectroscopic/fluorescent boronic acid showed a great interest for carbohydrate sensing. 
However, because of the limitations of the fluorescence properties of the boronic acid 
compounds, there was a need for the development of a general and sensitive method for the 
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determination of the binding constants between boronic acids and diols regardless of the 
boronic acids are fluorescent or not. Wang et. al. developed a generally applicable, highly 
sensitive method for the determination of the binding constants between boronic acids and diols 
by a three-component competition assay, Figure 1.5.33 ARS has been used for detection of 
boric acid.34 ARS is not a fluorescent molecule, because of the possible excited state proton 
transfer from one of the catechol dihydroxyl groups to the carbonyl oxygen.7 The binding of 
the catechol hydroxyl groups to the boronic acid should remove the phenol hydroxyl protons 
and abolish the excited state proton transfer process, which is responsible for the fluorescence.7 
O
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Figure 1.5. Proposed Alizarin Red S. (ARS) binding mechanism with boronic acid. 
 
1.5. Design of Fluorescent Boronic Acid Sensor 
Boronic acid compounds have been found to be a  great tool for carbohydrate diol binding 
because of their tight and reversible interactions with 1,2- or 1,3- diols. 22 Arylboronic acids are 
often used for this purpose.  In selecting arylboronic acids for carbohydrate recognition, those 
9  
that change fluorescent properties upon binding 26, 35-40 and are functional under physiological 
conditions 41-48 are especially useful. 7, 49  
 
 
 
 
 
 
Figure 1.6. Proposed binding di-boronic acid for Sialyl Lewis X tetrasaccharide. 
 
Such boronic acids have been used for a wide variety of applications including solution 
carbohydrate sensing,  50-61 cell labeling based on cell surface carbohydrate biomarkers, 62, 63 
erythrocyte agglutination 64 and carbohydrate transport and separations. 65-71 From this 
hypothesis, our strategically designed di-boronic acid compounds for specific recognition for 
certain cell lines.  
The first time Wang laboratory was demonstrated that synthetic fluorescent chemosensors can 
be used for a fluorescent labeling agent for over expressed saccharides in cancer cells. 28, 72 
This study showed that boronic acid compounds are able to specifically bind to over express 
targeted cells. SLex are over expressed in HEPG2 and HEP3B cancer cell lines. The picture on 
the right shows that non-expressing control cells (COS7) are not labeled. In Figure 1.7. SLex is 
over express in HEPG2 and HEP3B cancer cell lines. As a control, COS7 does not contain 
SLex saccharide. Presence of di-boronic acid HEPG2 and HEP3B cancer lines glove under UV. 
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However, COS7 cancer cell line does not glove under UV In this vendor, for many of the 
possible applications, the availability of a large number of structurally diverse fluorescent 
boronic acid moieties that change fluorescent properties will be very useful, especially for 
combinatorial synthesis of lectin mimics. Moreover, fluorescent boronic acid base 
chemosensors shows strong ability to binds to the carbohydrates. Chemical modifications of 
boronic acid sensors shown increase the specific gylycolipid binding. However, currently 
developed boronic acid sensors have highly conjugated hydrophobic properties. They required 
dissolving in organic co-solvent system for binding determination. However, these sensors 
were required large amount of organic co-solvents for increase the solubility. The solubility of 
fluorescent compounds is still one of the biggest challenges to apply these chemosensors in in 
vivo studies for medical applications.  
 
 
 
 
 
 
 
 
 
Figure 1.7. Fluorescent labeling of HEPG2, HEP3B, and COS7 with S23 and S3 at 5 mM.  
 
The purpose of this project is development of fluorescence carbohydrate sensors can be used in 
carbohydrate detection, diagnosis, analysis, and monitoring pathological processes in 
biomedical purposes. 
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Our first plan is develop small boronic acid compounds which are functional at physiological 
pH, change fluorescent upon binding with sugars and water soluble. 
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2. Synthesis and Evaluation of Dual Wavelength Fluorescent Benzo[b]thiophene Boronic 
Acid Derivatives for Sugar Sensing 
This part of the study has been published in Chemical Biology & Drug Design 2007, 70, 279-
289.  
Abstract 
Cell surface glycoproteins have been known to play very important roles in various 
physiological and pathological processes. Small molecule compounds capable of carbohydrate 
recognition can be very useful for the development of sensing, diagnostic, and therapeutic 
agents. Along this line, we are interested in developing water soluble fluorescent boronic acid 
compounds for carbohydrate recognition. As such, a series of benzo[b]thiophene boronic acid 
derivatives have been synthesized and their fluorescent properties analyzed at physiological 
pH. Benzo[b]thiophene derivatives were found to be a new type of fluorescent reporter 
compounds capable of dual fluorescent emission under physiological pH conditions. 
Compounds 1, 3, 4, 5 and 6 showed unusual emission wavelength shifts upon binding of 
sugars. These boronic acids will be useful tools for ts a unique example of a dual fluorescence 
carbohydrate sensor with an emission band shift. In order to exam whether this unusual dual 
emission fluorescent intensity phenomenon is general with different sugars, the binding of 1 
with sorbitol, galactose, mannose, and glucose was also tested. All tested sugars demonstrated 
the same dual emission spectral changes as fructose at physiological pH, Figure 2.3.  
2.1.Introduction 
Carbohydrates on cell surfaces are involved in many biological and pathological processes.1, 2 
Oligosaccharide binding proteins, lectins, specifically recognize certain oligosaccharides on the 
cell surface and trigger various biological events 3 such as  HIV infection, 4 cancer metastasis, 5 
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embryo development, 4 neural development, 6-8 and inflammation.9-11 Therefore, small 
molecules that mimic the function of lectins in recognizing carbohydrates can be used for 
various sensing, diagnosis, and therapeutic applications. 12 Development of such small 
molecule lectin mimics requires special recognition moieties capable of strong binding under 
physiological conditions. Along this line, boronic acid compounds hold a special place due to 
their strong interactions with sugars. Boronic acid compounds bind tightly and reversibly to cis 
1,2 or 1,3 diol moieties to form five- or six- membered rings, respectively.7, 13, 14  Arylboronic 
acids are often used for this purpose.  In selecting arylboronic acids for carbohydrate 
recognition, those that change fluorescent properties upon binding 15-21 and are functional under 
physiological conditions 22-29 are especially useful. 12, 30 Such boronic acids have been used for 
a wide variety of applications including solution carbohydrate sensing, 31-42 cell labeling based 
on cell surface carbohydrate biomarkers, 43, 44 erythrocyte agglutination 45 and carbohydrate 
transport and separations. 46-52  For many of the possible applications, the availability of a large 
number of structurally diverse fluorescent boronic acid moieties that change fluorescent 
properties will be very useful, especially for combinatorial synthesis of lectin mimics. Herein, 
we describe the synthesis and evaluation of five different benzo[b]thiophene boronic acid 
derivatives that change fluorescent properties upon binding to sugars at physiological pH, and 
can potentially be utilized for the synthesis of small molecule lectin mimics for carbohydrate 
biomarkers recognition.  These compounds are 2-benzo[b]thiophene boronic acid (2-BTBA, 1), 
3-benzo[b]thiophene boronic acid (3-BTBA, 2), 5-benzo[b]thiophene boronic acid (5-BTBA, 
3), 7-benzo[b]thiophene boronic acid (7-BTBA, 4), 4-benzo[b]thiophene boronic acid (4-
BTBA, 5), and 6-benzo[b]thiophene boronic acid (6-BTBA, 6), Figure 2.1. 
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Figure 2.1. The structures of benzo[b]thiophene boronic acid compounds.  
 
 
2.2. Synthesis 
The synthesis of 3-BTBA (2) is shown in Scheme 2.1. Bromination of 7 with molecular 
bromine at room temperature resulted in the dibrominated compound (8).53 The bromo group at 
the 2-position was removed with butyl lithium at -78 oC resulting in compound 9.  The 
protected boronic acid ester 10 was synthesized through a palladium catalyzed coupling 
reaction. 54-56 Deprotection of boronic acid ester57  was carried out via treatment with aqueous 
potassium hydrogen fluoride in methanol resulting in potassium benzo[b]thiophene 
trifluoroboronate salt 11. Hydrolysis of trifluoroborate with alkali metal hydroxide in 
acetonitrile resulted in free boronic acid compound 2.  
Benzo[b]thiophene boronic acid derivatives 3, 4, 5 and 6 were synthesized from their 
respective bromothiopenol derivatives in a similar fashion.7 Deprotonation of bromothiophenol 
with a strong base, NaH, followed by substitution with bromoacetaldehyde dimethyl acetal 
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resulted in compounds 13. Polyphosphoric acid-catalyzed aromatization at high temperatures 
resulted in 
bromobenzo[b]thiophenes 14.58  Catalytic borylation with bis(pinacolato)diboron was followed 
by hydrolysis to give the free boronic acid derivatives 3-6. 54-56 
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Scheme 2.1. Synthesis of 3-BTBA (2). 
Reagents and conditions: i) Br2, DCM, rt, 82%; ii) BuLi, THF, -78 oC, 81%; iii) 
bis(pinacolato)diboron, KOAc, [PdCl2(dppf)], DMSO, 80 oC, 61%; iv) KHF2, MeOH, rt, 85%;  
v) LiOH, CH3CN, rt, 90%. 
 
2.3. Fluorescent Studies 
The aim of the study was to search for boronic acid compounds that change fluorescent 
properties upon sugar binding. Therefore, the fluorescent properties of the compounds 
synthesized 2-6 and a commercially available analog 1 were examined in 0.1 M phosphate 
buffer at pH 7.4. We first examined compound 1, 2-BTBA.  The fluorescent spectral changes 
of 1 with addition of fructose at different concentrations are shown in Figure 2.2. In the 
absence of sugar, 2-BTBA shows two emission bands at 305 and 334 nm, respectively. 
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Following the addition of fructose, the fluorescent spectrum of 1 showed an increase in 
emission intensity at 305 nm and a wavelength shift of the 334 nm peak to 317 nm with a  
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Scheme 2.2. Synthesis of benzo[b]thiophene boronic acid derivatives 3, 4, 5 and 6. 
Reagents and conditions: i) NaH, bromoacetaldehyde dimethyl acetal, THF, reflux, 95-97%; ii) 
polyphosphoric acid, chlorobenzene,  160 oC, 82-96%; iii) bis(pinacolato)diboron, KOAc, 
[PdCl2(dppf)], DMSO, 80 oC, 47-65%; iv) KHF2, MeOH, rt, 60-70%; v) LiOH, CH3CN, rt, 61-
66%.   
 
somewhat decreased intensity. An isosbestic point was observed at 322 nm. This represents a 
unique example of a dual fluorescence carbohydrate sensor with an emission band shift. In 
order to exam whether this unusual dual emission fluorescent intensity phenomenon is general 
with different sugars, the binding of 1 with sorbitol, galactose, mannose, and glucose was also 
tested. All tested sugars demonstrated the same dual emission spectral changes as fructose at 
physiological pH, Figure 2.3.  
The apparent association constants (Ka) of compound 1 and five different sugars were also 
determined assuming 1:1 binding, Table 2.1. It is interesting to note that 2-BTBA showed 
somewhat higher binding constants than simple phenylboronic acid (PBA).   
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For example, under similar conditions, PBA showed the following binding constants: 370 M-1 
for sorbitol, 160 M-1 for fructose, 15 M-1 for galactose, 13 M-1 for mannose, and 4.6 M-1 for 
glucose. 59   
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Figure 2.2. Fluorescence spectra change of 1 (1 × 10-5 M) upon addition of D-fructose  
(0-5.0 mM) in 0.1 M phosphate buffer at pH 7.4: λex = 274 nm. 
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Figure 2.3. Relative fluorescence intensity of 1 (1 × 10-5 M) in 0.10 M phosphate buffer at pH 
7.4 in the presence of D-Sorbitol (■), D-fructose (♦), D-galactose (▲), D-mannose (x), and D-
glucose (*): λex = 274 nm, λem = 305 and 334 nm.   
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In contrast, the binding constants of 2-BTBA with the same sugars are as follows: 1008, 656, 
19, 27, and 30 M-1 respectively. The binding affinity trend for 2-BTBA also showed some 
difference from that of PBA with the binding constant for glucose higher than that of galactose 
and mannose. 
As has been shown before, boronic acid binding constants are affected by many factors such as 
the boronic acid pKa, boronic ester pKa, sugar pKa, pH, steric effect, buffer and its 
concentration, and the optimal binding pH of the boronic acid. 59, 60 The convoluted results of 
all these factors combined are not entirely predictable. In the absence of any sugar, the 
fluorescent intensity of 2-BTBA at 334 nm decreased upon changing pH from 3 to 12.  An 
apparent pKa of 7 was observed, which is assigned to the boronic acid moiety, Figure 2.4. In 
the presence of fructose, fluorescent intensity was tested in the region of pH 2 to 11. Similar to 
the situation in the absence of a sugar, the fluorescent intensity decreased at 334 nm with 
increasing pH. An apparent pKa of 4 was observed.  
Table 2.1.  Apparent association constants (Ka) of boronic acid sensors with different sugars 
and their apparent pKa values in the absence and presence of fructose. 
 2-BTBA (1) 
3-BTBA  
(2) 
5-BTBA 
(3) 
7-BTBA 
(4) 
4-& 6-BTBA   
(5 & 6) 
Phenylboronic 
acid (PBA)13 
Sorbitol 1008 ± 54 1883 ± 32 324 ± 33 4561 ± 90 349 ± 5 370 
Fructose   656 ± 28 1015 ± 30 256 ± 35 1342 ± 64 338 ± 37 160 
Galactose     19 ± 1     95 ± 29  6 ± 2 153 ± 2 12 ± 3 15 
Glucose     30 ± 1     22 ± 8 23 ± 3      38 ± 11 24 ± 11 13 
Mannose     27 ± 5     25 ± 2 2 ± 1     51 ±18 18 ±12 4.5 
pKa 7.0 8.5 8.6 8.0 8.2 8.8 
pKa 
+fructose 4.0 5.0 5.4 4.5 4.8 4.6 
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As has been demonstrated by past studies, boronic acids with lower pKa values than PBA tend 
to have higher binding constants. The apparent pKa of 7 for 2-BTBA is much lower than that 
of PBA (8.8) determined under similar conditions. 59, 60  This might be a major contributing 
factor for the higher binding constant for 2-BTBA.  The observed lowering of the boron pKa 
with fructose binding is also in line with what have been observed in the past with similar 
monoboronic acids. 59, 60 These results indicate that the boronic acid moiety of 2-BTBA exists 
partially in the tetrahedral ionized state, (1b, Scheme 2.3) at physiological pH even in the 
absence of a sugar, while in the presence of fructose the complex exists predominantly in the 
anionic state (1d, Scheme 2.3). The results further indicate that the free boronate (1b) 
fluorescent intensity is much higher than that of the free boronic acid (1a), while the 
fluorescent intensity of the sugar complex in the anionic state (1d) is much higher than that of 
the free boronate (1b).  
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Figure 2.4. Fluorescence intensity pH profile of 1 (1 × 10-5 M) in 0.10 M phosphate buffer: 
[saccharide] = 0.5 M, λex = 274 nm, λem = 334 nm. ♦ 1, ■1 + 0.5 M D-fructose.  
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Next, we were interested in studying whether positional analogs of 1 would show similar 
fluorescent property changes upon sugar binding.  Saccharide induced fluorescent changes of 
3-BTBA (2) were studied in a fashion similar to that of 2-BTBA (1b).  However, 3-BTBA 
exhibited significantly different fluorescent properties than 2-BTBA. Without sugar and at 
physiological pH, 3-BTBA displays two emission bands at 302 nm and 317 nm, respectively. 
Upon addition of fructose, the emission band at 302 nm exhibited little change, while the 
intensity of the emission band at 317 nm decreased. Furthermore, there was no wavelength 
shift observed either, Figure 2.5A. The lack of significant intensity changes at two wavelengths 
and emission shift are in direct contrast to 2-BTBA (1).  The effect of other carbohydrates was 
also tested with 3-BTBA (2). All sugars behaved similarly in changing the fluorescent 
properties of 3-BTBA, Figures 2.6A, 7A. 
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Scheme 2.3.  Proposed binding mechanism for compound 1 at different pH. 
The apparent association constants (Ka, Table 2.1) between 3-BTBA (2) and five different 
carbohydrates were determined.  These binding constants were also found to be higher than that 
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of PBA. pH induced fluorescent changes were also studied; fluorescence emission at 317 nm in 
the absence and presence of 0.5 M of sugar decreased upon changing pH from 2 to 12, Figure 
2.8A. An apparent pKa was observed at 8.5 in the absence of sugar and 5.2 in the presence of 
fructose, Figure 2.8A.  In this case, the improved binding constant cannot be readily associated 
with the pKa change as in the case of 2-BTBA.   
 
Figure 2.5. Fluorescence spectral changes of boronic acid compounds 2-6 with different 
concentrations of D-fructose (0-50 mM) in 0.1 M aqueous phosphate buffer at pH 7.4. A) 3-
BTBA (2, 1.0 × 10-5 M), λex = 274 nm; B) 5-BTBA (3, 1.0 × 10-5 M), λex = 274 nm; C) 7-
BTBA (4, 1.0 × 10-5 M), λex = 274 nm; D) 4 & 6-BTBA (5 & 6, 1.0 × 10-5 M), λex = 264 nm.  
 
However, this is not strange as the binding constants are affected by many factors and there are 
numerous cases that the boronic acid binding constants do not correlate with its pKa. 59, 60 In 
other words, there is no good way to predict precise boronic acid-sugar binding constants yet 
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indicate that positional isomers within this series of compounds may show very different 
fluorescent property changes upon sugar binding. For 5-BTBA (3), two emission bands at 303 
and 322 nm were observed in the absence of a sugar. Upon the addition of fructose, the 
fluorescent spectrum of 3 showed an increase in emission intensity at 303 nm.  The emission 
band at 322 nm shifted to 315 nm and showed an isosbestic point at 322 nm (Figure 2.5B). This 
is very similar to the situation of 2-BTBA (1). 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.00 0.01 0.02 0.03 0.04 0.05
[sugar]
Δ
I/I
o
B. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0.00 0.01 0.02 0.03 0.04 0.05
[sugar]
Δ
I/I
o
C.  
0
0.5
1
1.5
2
2.5
3
3.5
4
0.00 0.01 0.02 0.03 0.04 0.05
[sugar]
 Δ
I/I
o
D. 
A. 
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.00 0.01 0.02 0.03 0.04 0.05
[sugar]
Δ
I/I
o
 
Figure 2.6. Fluorescence intensity changes (ΔI/Io) of boronic acid 2-6 (1 × 10-5 M) in aqueous 
phosphate buffer at pH 7.4 in the presence of D-Sorbitol (♦), D-fructose (■), D-galactose (▲), 
D-mannose (◊), and D-glucose (●) with different sugar concentration:  A. 3-BTBA (2), λex = 
274 nm, λem = 317 nm. B. 5-BTBA (3), λex = 274 nm, λem = 302 nm. C. 7-BTBA (4), λex = 274 
nm, λem = 303 nm. D. 4-BTBA (5) and 6-BTBA (6), λex = 267 nm, λem = 303 nm. 
 
 
To study the generality of this fluorescent behavior, we also tested sorbitol, galactose, 
mannose, and glucose.  Similar to the situation of boronic acids 1 and 2, all sugars induced 
similar trends in fluorescent property changes, Figures 2.6B, 7B. The apparent binding 
constants (Ka) between compound 3 and five sugars were further investigated. 5-BTBA (3) 
showed moderate binding affinity to sorbitol (324 M-1) and fructose (256 M-1) and low affinity 
32 
 
 
for galactose, mannose, and glucose, Table 2.1. However, it still exhibited higher association 
constants than PBA for glucose. The apparent pKa was found to be 8.6 in the absence of 
fructose and 5.2 in the presence of fructose, Figure 2.8B.  
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Figure 2.7. Relative fluorescence intensity of boronic acid compounds 3-6 (1 × 10-5 M) in 0.10 
M phosphate buffer at pH 7.4 in the presence of D-Sorbitol (♦), D-fructose (■), D-galactose 
(▲), D-mannose (◊), and D-glucose (●): A. 5-BTBA (3), λex = 274 nm, λem = 302 nm and 
334nm. B. 7-BTBA (4), λex = 274 nm, λem = 303 nm and 334 nm. C. 4-BTBA (5) and 6-BTBA 
(6), λex = 267 nm, λem = 303 nm and 329 nm. 
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7-BTBA (4) exhibited similar fluorescent property changes upon sugar addition as 2-BTBA (1) 
and 5-BTBA (3), Figure 2.5C. Without sugar, 4 exhibited two emission bands at 303 nm and 
334 nm when excited at 274 nm in phosphate buffer at pH 7.4. 
 
 
Figure 2.8. pH profiles of fluorescence intensity changes of boronic acids 2-6 (1 × 10-5 M) in 
the absence and presence of D-fructose (0.5 M) in 0.1 M aqueous phosphate buffer. A. 3-
BTBA (2), λex = 274 nm, λem = 318 nm; B. 5-BTBA (3), λex = 270 nm , λem = 324 for free 
boronic acid, λem = 313 nm for boronic acid + 0.5 M D-fructose; C. 7-BTBA (4), λex = 274 nm, 
λem = 315 nm; D. 4-BTBA (5) and 6-BTBA (6), λex = 267 nm, λem = 332 nm; ♦boronic acid, ■ 
boronic acid + 0.5 M D-fructose. 
 
 
With the addition of fructose, compound 4 showed fluorescence intensity increases at 303 nm, 
while the emission band at 334 nm shifted to 314 nm with a somewhat increased intensity.  An 
isosbestic point was observed at 326 nm. Other tested sugars showed dual band emission 
phenomena similar to fructose, Figure 2.6c and 7c. The apparent pKa was observed at 8.0 in 
the absence of sugar and 5.0 in the presence of fructose, which is consistent with the general 
phenomena that binding to sugars lowers the pKa of a boronic acid. 13  One very unique feature 
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that stands out with 7-BTBA is its large apparent binding constants with various sugars. For 
example, the binding constants of 7-BTBA with sorbitol, fructose, galactose, mannose, and 
glucose were 4561, 1342, 153, 51, and 38 M-1, respectively.  In contrast, the apparent binding 
constants with the same sugars under identical conditions for PBA were much smaller, Table 
2.1. 59, 60  Again, it does not seem that there is a direct correlation between the pKa of either the 
free boronic acid or the boronic ester with the drastically improved binding constants for 7-
BTBA.  Further theoretical studies are underway to examine this issue.  
The fluorescent properties of 4-BTBA (5) and 6-BTBA (6) were examined as a mixture due to 
the difficulty in separating these two compounds. Without sugar, the mixture of 5 and 6 showed 
two emission bands at 293 nm and 329 nm when excited at 267 nm, Figure 2.5D. Upon 
addition of fructose, the emission band at 293 nm shifted to 303 nm and increased in 
fluorescent intensity.  Additionally, the emission band at 329 nm shifted to 314 nm with a 
slight increase in fluorescent intensity. An isosbestic point was observed at 327 nm. Among the 
tested benzo[b]thiophene boronic acid derivatives, only the mixture of 5 and 6 showed both a 
red shift and a blue shift at the same time. The results were similar when tested with other 
sugars such as sorbitol, galactose, glucose, and mannose.  The apparent association constants 
(Ka) for this mixture were also determined, Table 2.1. These binding constants are comparable 
to that of 5-BTBA, but much smaller than that of 7-BTBA.  The apparent pKa of this mixture 
was determined to be 8.2 in the absence of any sugar and 4.8 in the presence of 0.5 M fructose, 
consistent with all previous findings that sugar addition lowers the pKa of the boronic acid 
moiety. It is interesting to note that the fluorescence studies indicate that the 4-BTBA and 6-
BTBA mixture shows dual fluorescent properties. Since these isomers were not isolated, it is 
hard to make an assumption of characteristic fluorescent properties of each isomer. Since the 
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mixture of 4- and 6-BTBA showed similar fluorescent properties with other isomers and their 
separation was very hard, we did not pursue the study with individual isomers.  
2.4. Conclusion 
In conclusion, six benzo[b]thiophene boronic acid derivatives have been examined for their 
fluorescent property changes upon sugar binding.  All six compounds showed significant 
fluorescent property changes upon sugar addition.  Among them, 2-, 5, and 7-BTBA showed a 
pattern of fluorescent property changes with intensity increase at one wavelength and a blue 
shift coupled with an intensity change in another.  Such changes allow for ratiometric sensing.  
3-BTBA only showed fluorescent intensity changes at one wavelength.  The mixture of 4- and 
6-BTBA showed a very unique red shift at one wavelength and blue shift in another upon sugar 
addition.  Work is currently underway to use these new fluorescent reporter compounds for the 
synthesis of di- and polyboronic acid sensors for high selectivity identification and detection of 
carbohydrates of biological interest.   
2.5. Experimental  
2.5.1. General Information 
2-Benzothiophene boronic acid was purchased from Frontier Scientific (Logan, UT, USA) and 
other reagents and sugars from Acros (Morris Plains, NJ, USA) and Aldrich (St Louis, MO, 
USA). Moisture sensitive reactions were carried out under dried N2 with oven dried glassware. 
Purification of crude materials was completed with flash chromatography with silica gel 60 
(230-400 mesh) from Sorbient Technology (Atlanta, GA, USA). THF was distilled from Na 
and benzophenone. 1H NMR and 13C NMR spectra were recorded at 400 MHz and 100 MHz, 
respectively. Mass spectrum analyses were performed by the Georgia State University 
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Analytical Facilities. Chemical shifts (δ) are given in ppm relative to TMS for 1H spectra and 
residual solvents for 13C spectra. 
2.5.2. Fluorescence binding studies 
Fluorescent spectra were recorded on a Shimadzu RF-5301 PC spectrofluorometer. Absorption 
spectra were recorded on a Shimadzu UV-1700 UV/Vis spectrometer. pH values were 
determined by a UB-10 Ultra Basic Benchtop pH meter (Denver Instrument, Denver, CO, 
USA). Distinct solutions of the sensors (1.0 × 10-5 M) were prepared in 0.1 M phosphate buffer 
at pH 7.40. Stock sugar solution was prepared by using sensor solution and the required amount 
of sugar dissolved in a volumetric flask.  To prepare various concentrations of sugars, the stock 
sugar-sensor solution was diluted with sensor solution. Binding constants and apparent pKa 
values were measured as described earlier. 23, 25, 28 
2.5.3. Synthetic Procedures  
2,3-Dibromobenzo[b] thiophene (8).53 
2.3-Dibromobenzo[b]thiophene 8 was synthesized by following literature procedures. 
3-Bromobenzo[b]thiophene (9).61  
3-Bromobenzo[b]thiophene 9 was prepared by following literature procedures.  
2-Benzo[b]thiophen-3-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (10).  
KOAc  (1.1 g 11.4 mmol) was added to a solution of compound 9 (485 mg, 2.28 mmol), 
bis(pinacolato)diboron (867 mg, 3.41 mmol), and PdCl2(dppf) (93 mg, 0.01 mmol) in 
anhydrous DMSO (7 mL). The reaction mixture was stirred at 80 oC overnight. Solution was 
dissolved in ethyl acetate 100 mL and washed with 5% NaHCO3 (5 × 20 mL) and dried over 
Na2SO4. After filtration and evaporation of the solvent, the crude product was purified by 
column chromatography with 30 g of silica gel eluting with hexanes/ethyl acetate (5:1) to give 
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compound 10 as a colorless solid (360 mg, 61%). 1H NMR (CDCl3): δ 8.37 (d, J = 7.2 Hz, 1H), 
8.06 (s, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.41-7.02 (m, 2H), 1.37 (s, 12H); 13C NMR (CDCl3): δ 
142.8, 140.7, 139.0, 125.4, 124.3, 124.1, 122.1, 83.5, 24.9; GC-MS: m/z calculated for 
C14H17BO2S: 260, found: 260 (M).  
Potassium 3-benzo[b]thiophene trifluoroborate (11). 
 To the solution of compound 10 (213 mg, 0.8 mmol) in 10 mL of methanol was added aqueous 
potassium hydrogen fluoride (351 mg, 4.5 mmol, 4.5 M).  The mixture was stirred at room 
temperature for 4 hr. Then solvent was removed under vacuum and the residue was dissolved 
in hot acetone. The mixture was filtered.  The filtrate was collected and solvent was removed in 
vacuo.  An oily yellow residue was obtained, which was crystallized in a minimum amount of 
acetone and 10 mL of ethyl ether to give compound 11 as a white solid (163 mg, 85%). 1H 
NMR (d6-acetone): δ 8.18 (m, 1H), 7.80 (m, 1H), 7.24 (s, 1H), 7.22-7.14 (m, 2H). 13C NMR 
(d6-acetone ): δ 142.8, 140.7, 139.0, 125.4, 124.3, 124.1, 122.1; ESI-MS: m/z calculated for 
C8H5BF3SK: 240; found: 201 (M-K). 
3-Benzo[b]thiophene boronic acid (3-BTBA, 2).62  
Compound 11 (163 mg, 0.68 mmol) and lithium hydroxide were dissolved in acetonitrile (5 
mL) and water (1 mL). The solution was stirred at room temperature for 36 hr and then 
acidified with conc. hydrochloric acid. Then solvent was removed in vacuo to give a residue, 
which was dissolved in ethyl acetate (30 mL) and washed with 5% NaHCO3 (2 × 20 mL). The 
organic layer was dried over Na2SO4. Removal of solvent through filtration and rota-
evaporation afforded a white solid compound 2 (107 mg, 90%).  1H NMR (d6-DMSO, D2O): δ  
8.37 (d, J = 7.6 Hz, 1 H), 8.24 (s, 2H), 8.21 (s, 1H), 7.98 (d, J = 7.2 Hz, 1H), 7.38-7.30, (m, 
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2H). 13C NMR (d6-DMSO, D2O): δ 143.3, 140.7, 137.7, 126.0, 124.3, 124.2, 122.6. ESI-MS: 
m/z calculated for C8H7BO2S:178, found: 177 (M - H).  
1-Bromo-4-(2,2-dimethoxy-ethylsulfanyl)-benzene (13a).  
 3-Bromobenzothiol 12a (500 mg, 2.6 mmol) was dissolved in 20 mL fresh distilled THF; 
sodium hydride (140 mg, 3.4 mmol, in 60% mineral oil) was added in the flask.  The mixture 
was stirred for 10 min. at rt and then bromoacetaldehyde dimethylacetal (41 mL, 3.4 mmol) 
was injected into the flask.  Next, the reaction mixture was refluxed for 24 hr. After solvent 
evaporation, the residue was dissolved in ethyl acetate (50 mL), washed with a saturated 
solution of NaHCO3 (3 × 30 mL), and dried over Na2SO4. After filtration and evaporation of 
the solvent, the crude product was purified by column chromatography with 10 g of silica gel 
eluting with hexanes/DCM (5:1) to give a pale green oil, compound 13a (680 mg, 95%). 1H 
NMR (CDCl3): δ 7.41-7.38 (m, 2H), 7.26-7.23 (m, 2H), 4.50 (t, J = 5.6 Hz, 1H), 3.36 (s, 6H), 
3.09 (d, J = 5.6 Hz, 2H). 13C NMR (CDCl3): δ 135.4, 131.9, 131.0, 120.1, 103.1, 53.6, 36.5. 
GC-MS: m/z calculated for C10H13BrO2S: 276, found: 276 (M).  
5-Bromobenzo[b]thiophene (14a).  
Polyphosphoric acid (500 mg) and cholorobenzene (15 mL) mixture was refluxed for 3 hours 
and then compound 13a in 3 mL of cholorobenzene (240 mg, 0. 8 mmol) was injected  into the 
flask. The reaction mixture was refluxed for an additional 24 hr while silicon oil temperature at 
was maintained at 180 oC . Cholorobenzene was then evaporated in vacuo and the resulting 
residue dissolved in DCM (50 mL).  The solution was washed with NaHCO3 solution (3 × 30 
mL) and dried over Na2SO4. After filtration and evaporation of the solvent, the crude product 
was purified by column chromatography with 10 g of silica gel eluting with hexanes to give a 
pale yellow oil (180 mg, 82%). 1H NMR (CDCl3): δ 7.91 (d, J = 2.0 Hz, 1H), 7.68 (d, J = 9.0 
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Hz, 1 H), 7.42 (d, J = 5.6 Hz, 1H), 7.39 (dd, J1 = 2.0 Hz, J2 = 9.0 Hz, 1H), 7.21 (dd, J1 = 0.4 Hz, 
J2 = 5.6 Hz, 1H); 13C NMR (CDCl3): δ 141.1, 138.2, 128.0, 127.1, 126.1, 123.6, 123.0, 118.1; 
GC-MS: m/z calculated for C8H4BrS: 212, found: 212 (M).  
2-Benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (15a).  
 Compound 15a was synthesized from compound 14a by following similar procedures used for 
the synthesis of 10. The crude product was purified by silica gel column chromatography 
eluting with hexanes/ethyl acetate (2:1) to give compound 15a as a colorless solid (60%).  1H 
NMR (CDCl3): δ 8.31 (s, 1 H), 7.89 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 
5.6 Hz, 1H), 7.35 (d,  J = 5.6 Hz, 1H), 1.37 (s, 12H); 13C NMR (CDCl3): δ  142.7, 139.1, 130.7, 
129.7, 126.0, 124.1, 121.8, 83.8, 24.9; GC-MS: m/z calculated for C14H17BO2S: 260, found: 
260 (M).  
Potassium 5-benzo[b]thiophene trifluoroborate (16a).  
Compound 16a was synthesized from compound 15a by following the same procedure as for 
the synthesis of 11. The crude product was purified by crystallization with minimum amount of 
acetone and 10 mL of ether to give compound 16a as a white solid (70%). 1H NMR (d6-
acetone): δ 7.98 (s, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 5.6 Hz, 
1H), 7.28 (d, J = 5.6 Hz, 1H); 13C NMR (d6-acetone): δ 139.0, 137.0, 129.0, 126.4, 124.1, 
123.6, 119.8; ESI-MS: m/z calculated for C8H5BF3SK: 240; found: 201 (M - K). 
5-Benzo[b]thiophene boronic acid (5-BTBA, 3).  
Compound 3 was synthesized from hydrolysis of 16a by following the same procedures used 
for the synthesis of 2, to give 3 as a white solid (66%). 1H NMR (d6-DMSO): δ  8.31 (s, 1H), 
8.09 (s, 2H), 7.95 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 5.6 Hz, 1H), 7.46 
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(d, J = 5.4 Hz, 1H); 13C NMR (d6-DMSO): δ 141.3, 139.0, 130.3, 130.0, 127.1, 124.6, 121.9; 
ESI-MS: m/z calculated for C8H7BO2S: 178; found: 177 (M - H). 
1-Bromo-2-(2,2-dimethoxy-ethylsulfanyl)-benzene (13b).  
Compound 13b was synthesized from 2-bromobenzothiol by following the procedure used for 
the synthesis of 13a, and the crude product was purified by column chromatography with silica 
gel eluting with hexanes to give 13b as pale yellow oil (95%). 1H NMR (CDCl3): δ 7.53 (dd, J1 
= 1.2 Hz, J2 = 8.0 Hz, 1H), 7.33 (dd, J1 = 1.6 Hz, J2 = 7.6 Hz, 1H), 7.32 (dt, J1 = 1.2 Hz, J2 = 7.2 
Hz, 1H), 7.03 (dt, J1 = 1.6 Hz, J2 = 7.6 Hz, 1H), 4.58 (t, J = 5.6 Hz, 1H), 3.37 (s, 6H), 3.13 (d, J 
= 5.6 Hz, 2H); ),13C NMR (CDCl3): δ 137.5, 133.0, 129.1, 127.7, 127.0, 124.2, 103.1, 53.6, 
36.0; GC-MS: m/z calculated for C10H13BrO2S: 276, found: 276 (M).  
7-Bromobenzo[b]thiophene (14b).  
Compound 14b was synthesized from 13b by following the same procedure used for the 
synthesis of 14a, and the crude product purified by column chromatography with silica gel 
eluting with hexanes to give 14b as a colorless oil (85%). 1H NMR (CDCl3): δ 7.73 (dd, J1 = 
0.8 Hz, J2 = 8.0 Hz, 1H), 7.47-7.45 (m, 2H), 7.39 (d, J = 5.6 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H); 
13C NMR (CDCl3): δ 141.5, 140.5, 127.2, 127.0, 125.4, 124.7, 122.5, 115.8; GC-MS: m/z 
calculated for  C8H4BrS: 212; found: 212 (M). 
2-Benzo[b]thiophen-7-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (15b).  
Compound 15b was synthesized via palladium catalyzed coupling with 14b by following the 
same procedure used for the synthesis of 15a.  The crude product was purified by column 
chromatography eluting with hexanes/ethyl acetate (2:1) to give compound 15b as a white solid 
(65%). 1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J1 = 1.2 Hz, J2 = 8.0  Hz, 1H), 7.82 (dd, J1 = 
0.8 Hz, J2 = 6.8  Hz, 1H), 7.46 (d, J = 5.6 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 5.6 Hz, 
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1H), 1.42 (s, 12H) ; 13C NMR (CDCl3): δ 145.7, 139.2, 131.8, 127.4, 126.5, 123.5, 123.2, 84.2, 
24.9; GC-MS: m/z calculated for C14H17BO2S: 260, found: 260 (M).  
Potassium 5-benzo[b]thiophene trifluoroborate (16b).  
Compound 16b was synthesized from compound 15b by following equivalent reaction 
procedures to those used for synthesis of 11. The crude product was purified by  crystallization 
with a minimum amount of acetone and 10 mL of ether, to give compound 16b as a white solid 
crystals (60%). 1H NMR (MHz, d6-acetone): δ 7.59 (dd, J1 = 0.8 Hz, J2 = 7.6 Hz, 1H), 7.46 (d, J 
= 6.8 Hz, 1H), 7.42 (d, J = 5.6 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 7.17 (dt, J1=0.4 Hz, J2 = 7.4 
Hz, 1H); 13C NMR (d6- acetone): δ 143.5, 138.2, 127.0, 126.9, 122.8, 122.6, 120.6; ESI-MS: 
m/z calculated for C8H5BF3SK: 240, found: 201 (M - K).  
7-Benzo[b]thiophene boronic acid (7-BTBA, 4).  
Compound 4 was synthesized by hydrolysis of 16b following the procedure used for the 
synthesis of 2 to give 4 as a white solid (61%).  1H NMR (d6-DMSO, D2O): δ 8.38 (s, 2H), 7.93 
(d, J = 8.0 Hz, 1H), 7.83 (d, J = 6.8 Hz, 1H), 7.71 (d,  J = 5.6 Hz, 1H), 7.42-7.35 (m, 2H); 13C 
NMR (d6-DMSO, D2O): δ 145.1, 139.5, 131.2, 128.7, 126.0, 123.8, 123.6; ESI-MS: m/z 
calculated for C8H7BO2S: 178, found: 177 (M-H). 
1-Bromo-3-(2,2-dimethoxy-ethylsulfanyl)-benzene (13c). 
 Compound 13c was synthesized from 3-bromobenzothiol by following the same procedure 
used for the synthesis of 13a, and the crude product was purified by column chromatography 
with silica gel eluting with hexanes/DCM (5:1) to give 13c as pale yellow oil (97%). 1H NMR 
(CDCl3): δ 7.52 (m, 1H), 7.33-7.29 (m, 2H), 7.17-7.13 (m, 1H), 4.55 (t, J = 5.6 Hz, 1H), 3.39 
(s, 6H), 3.13 (d, J = 5.6 Hz, 2H); 13C NMR (CDCl3): δ138.7, 131.4, 130.1, 129.1, 127.5, 122.7, 
103.0, 53.6, 36.2; GC-MS: m/z calculated for C10H13BrO2S: 276, found: 276 (M). 
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4-Bromo benzo[b]thiophene and 6-bromo benzo[b]thiophene (14c,d).63  
Aromatic cyclization of 13c was accomplished by following the same procedure used for the 
synthesis of 14a. After purification by column chromatography with silica gel eluting with 
hexanes/DCM (5:1) a mixture of 4-bromo benzo[b]thiophene and 6-bromo benzo[b]thiophene 
was obtained as yellow oil (96%). 1H NMR (CDCl3): δ 7.96 (m, 1H), 7.74 (d, J = 8.4 Hz, 1H), 
7.59 (d, J =8.4 Hz, 1H), 7.49 (dd, J1 = 0.8 Hz, J2 = 7.8 Hz, 1H), 7.44-7.40 (m, 3H), 7.34 (d, J = 
5.6 Hz, 1H), 7.22 (dd, J1= 0.4,  J2 = 5.6 Hz, 1H), 7.12 (t, J = 5.6 Hz, 1H); 13C NMR (CDCl3): δ 
141.3, 140.5, 139.5, 138.3, 127.6, 127.5, 127.3, 127.0, 125.2, 125.0, 124.7, 124.3, 123.6, 121.6, 
118.2, 117.5; GC-MS: m/z calculated for C8H4BrS: 212, found: 212 (M). 
2-Benzo[b]thiophen-4-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (15c) and 2-benzo 
[b]thiophen-6-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (15d).  
Boronic acid ester mixture (15c,d) was synthesized via palladium catalyzed coupling with the 
4-bromo benzo[b]thiophene and 6-bromo benzo[b]thiophene mixture by following the same 
procedure used for the synthesis of 15a.  The crude product was purified by column 
chromatography eluting with hexanes/ethyl acetate (2:1) to give a mixture of the ester 
compounds (15c,d) as a white solid (47%). 1H NMR (CDCl3): δ 8.40 (s, 1H), 8.05-7.787 (m, 
5H), 7.50 (t, J = 5.6 Hz,  2H), 7.35 (t, J = 8.8 Hz, 2H), 1.45 (s, 12H), 1.40 (s, 12H); 13C NMR 
(CDCl3): δ 144.1, 141.8, 139.6, 139.3, 132.4, 129.8, 129.6, 128.2, 126.5, 125.9, 125.4, 123.9, 
123.4, 123.0, 83.9, 83.8, 25.0, 24.9; GC-MS: m/z calculated for C14H17BO2S: 260; found: 260 
(M).  
4- and 6-Benzo[b]thiophene boronic acid mixture (4-BTBA, 5; 6-BTBA, 6).  
Boronic acid mixture (5, 6) was synthesized from the mixture of 15c,d following the same 
procedures used for the synthesis of 11. The crude product was purified with crystallization 
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with a minimum amount of acetone and 10 mL of ether to give the potassium trifluoroborate 
mixture as a white solid.  Hydrolysis of the salt following the same procedure used for the 
synthesis of 2 gave 5 and 6 as a white solid (61%). Proton NMR and carbon NMR is given for 
the mixture. 4-BTBA: 1H NMR (d6-DMSO,  D2O): δ 8.50 (s, 2H), 7.92 (d, J= 8.0 Hz, 1H), 7.78 
(d, J = 6.8 Hz, 1H), 7.73 (d, J = 5.2 Hz, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H); 
6-BTBA: 1H NMR (d6-DMSO, D2O): δ 8.28 (s, 1H), 8.24 (s, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.73 
(d, J = 8.0 Hz, 1H), 7.65 (d, J = 5.2 Hz, 1H), 7.44 (d, J = 5.2 Hz, 1H).13C NMR (DMSO, d6, 
D2O): δ 145.0, 141.5, 139.5, 139.4, 131.2, 130.2, 129.9, 128.5, 127.2, 126.1, 124.7, 123.9, 
123.6, 122.0; ESI-MS: m/z calculated for C8H7BO2S: 178, found: 177 (M-H). 
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SECTION II 
DNA-MINOR GROOVE BINDERS AS ANTIPARASITIC AGENTS 
3. Parasitical Diseases 
The classical Greek word “parasite” was described as “a guest who comes to dinner and doesn't 
leave.” However, today’s biology uses the term to describe eukaryotic organisms, which range 
from a single cell protozoa to complex multicellular worms, which grow and multiply in host 
organelles. The diseases caused by these organisms represent some of the world's greatest 
health problems. 
3.1. Human African Trypanosomiasis (HAT, Sleeping Sickness) 
Human African Trypanosomiasis (HAT), or sleeping sickness, is one of the most deadly 
diseases in sub-Saharan Africa. The most common form of human African trypanosomiasis is 
caused by the vector borne parasite, Trypanosoma brucei. The parasite is transmitted by tsetse 
fly (Glossina Genus) bites.  Devastating epidemics of Trypanosoma brucei have occurred in 
large areas of Central Africa, especially the Southern Sudan, Congo-Zaire, Angola, Uganda and 
the Central African Republic.1 According to the World Health Organization, the annual 
incidence of the disease is approximately 300,000 cases, with 500,000 people already carrying 
trypanosomes and the majority of these cases will die if left untreated. In addition, the large 
habitat area of the tsetse fly threatens 60 million people over approximately ten million square 
kilometers in sub Saharan Africa.2, 3  
Trypanosomiasis sickness in humans is caused by two different subspecies of Trypanosoma 
brucei: Trypanosoma brucei rhodensiense (T.b.r.) in Eastern Africa and Trypanosoma brucei 
gambiense (T.b.g.) in Western Africa. Both forms of the parasite affect the central nervous 
system.  
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Trypanosoma brucei rhodesiense causes an acute infection within a few weeks after infection 
with the parasite. The disease develops rapidly and invades the central nervous system. 
Trypanosoma brucei gambiense also causes an acute infection. However, the first symptoms 
may become apparent only months or even years after the initial infection. Because of the slow 
developing symptoms, the disease is often not diagnosed until the disease is in an advanced 
state.  
Infections occur during a blood meal by the tsetse fly when the parasite is transmitted to the 
mammalian host.  However, the parasite does not keep the same kinetoplastic form after 
leaving the insect. Different morphological forms are associated with different life cycle stages 
in the various species. The different life forms of the parasite are distinguished by the position 
of the kinetoplastid in relation to the nucleus and the presence or absence of an undulating 
membrane. Four major morphological forms are found in kinetoplastids that cause sleeping 
sickness. First, the tsetse fly injects metacyclic trypomastigotes into mammalian skin tissue.  
The parasites enter the lymphatic system through the skin and travel to different organs via the 
blood stream. In the bloodstream of the host, the parasite transforms into trypomastigotes and 
continues the replication by binary fission. The tsetse fly becomes infected with 
trypomastigotes when taking blood from an infected mammalian host. The parasites transform 
into procyclic trypomastigotes in the fly’s midgut and multiply by binary fission. The new form 
then leaves the midgut and transforms into epimastigotes in the fly’s salivary glands and again 
multiply by binary fission. The next cycle starts again with an infected fly bite. 4 
The symptoms of trypanosomiasis vary between subspecies of the invading parasite. During the 
trypomastigotes’ incubation period, the infection is characterized by irregular episodes of fever 
and headache. In the case of T.b.g., the number of parasites in the blood tends to be very low 
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and often the infected person shows no symptoms. However, the patients infected with T.b.r. 
show much higher parasitemias and a more pronounced fever.   
Trypanosomes that cross the blood-brain barrier result in a generalized meningoencephalitis 
which causes central nervous system (CNS) damage and shows worsening symptoms including  
apathy, fatigue, confusion, somnolence, and motor changes (such as tics, slurred speech, and 
lack of coordination).  Neurological manifestations can occur within weeks after T.b.r.  
infections. If patients are not treated at the CNS stage of the disease, it will usually progress to 
convulsions or coma followed by death in both T. b.g.  and T.b.r. infections.   
Advanced identification agents and serological tests are available for diagnosis of the parasite 
in blood samples, lymph node aspirations, or spinal fluid. The diagnosis follows a 3-step 
approach: screening, parasitological confirmation and staging. The staging step is essential 
because the treatment of the first and second stage of the disease are very different.5 However, 
these tests are costly and require complicated instrumentation. Therefore, it is a huge problem 
in rural areas in Africa. 
3.1.1. Treatment of Human African Trypanosomiasis 
Different medication has been used depending on the type and stage of African 
trypanosomiasis. Suramin and pentamidine are the recommended drugs during the acute 
hemolymphatic stage.6 However, melarsoprol or eflornithine are recommended if the CNS is 
involved.7 Nifurtimox, in  combination with eflornithine, is used for late stage treatment.8 
3.1.2. Drugs Used in Hemolymphatic Stage 
Suramin  
Suramin is a polysulfonated naphthylamine derivative of urea that was synthesized in 1916 and 
marketed in 1922 as an antiparasitic agent.  It is the drug  used for  early-stage African 
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trypanosomiasis and onchocerciasis.9 Suramin is trypanocidal and works by inhibiting parasitic 
enzymes and growth factors.10, 11 A number of negative charges on the drug increases the 
electrostatic interaction and the ligand binds to many enzymes with a high affinity. Suramin is 
highly bound to serum proteins, therefore the drug can not cross the blood-brain barrier.12 
Suramin is more effective and less toxic than pentamidine. 
Pentamidine isethionate  
This antiprotozoal diarylamidine agent was first developed in 1941 and is typically used for the 
early stage of African trypanosomiasis. It is also used for Pneumocystis carinii pneumonia and 
leishmaniasis.13-17 The mitochondrion appears to be a target for pentamidine in various species 
including yeast.18 The dicationic property of pentamidine facilitates electrostatic interaction 
with cellular polyanions such as circular DNA molecules. Pentamidine has been suggested to 
inhibit the dihydrofolate reductase enzyme and thereby interfere with parasite aerobic 
glycolysis.19 Pentamidine is administered by injection due to poor gastro-intestinal (GI) 
absorption, and is strongly bound to tissues, including the spleen, liver, and kidney. 
Pentamidine does not penetrate the blood-brain barrier effectively and, therefore, it is not used 
to treat CNS infection.20, 21 
3.1.3. Drugs Used in the Neurological Stage  
Melarsoprol  
This trivalent arsenical compound was synthesized in 1949 and is used in the late stage of 
African trypanosomiasis, despite its extremely toxic side effects.22, 23 Melarsoprol kills 
trypanosomes rapidly by inhibiting parasitic glycolysis which causes ATP loss.24 The drug is 
administered by direct injection, and can penetrate the blood brain barrier to levels of only 
around 1–2% of the maximum plasma levels.25 The therapy often has a 90-95% success rate in 
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clearing the parasitemia. However, the drug is highly toxic and may cause fatal complications 
in 5 to 10% of patients.   
Eflornithine  
α-Difluoromethylornithine was developed in the early 1980s as a cancer treatment. However, 
the drug was found to be highly effective for treatment of only the West African form (T.b.g.) 
of trypanosomiasis.26 This drug has been used for treatment of patients in the late stages of the 
disease. The drug is a selective and irreversible inhibitor of ornithine decarboxylase, which is a 
critical enzyme for DNA and RNA synthesis.27, 28 Eflornithine is generally tolerated better and 
is less toxic than arsenic drugs and it is used for patients who are infected with T.b.r. and 
cannot tolerate melarsoprol.  
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3.1.4. Drugs Entered into Clinical Trials  
Pafuramidine maleate (DB 289) 
The usage of the furamidine (DB 75) has been limited due to its toxicity and bioavailability. 
DB 75  was chemically modified to form the prodrug pafuramidine maleate (DB 289).29 The 
prodrug is metabolized to furamidine after cellular uptake. Studies showed that the prodrug 
strategy was successful in the terms of reducing toxicity and increasing efficacy. In addition, 
DB 289 can be administered orally.30 DB 289 successfully cleared parasitical infections in 
animal models. While the mechanism of action is not fully understood, it is known that DB 289 
is metabolized to DB 75 which causes mitochondrial damage in the parasite.31  The compound 
was removed from trials due to renal toxicity.  
Diminazene  
Diminazene, a diamidine product also known as Bernil, was first registered as a veterinary 
trypanocide.32  However, human trials also resulted in promising trypanocidal activity.33 The 
drug enters the trypanosomes via the P2 transporter and binds to the DNA.34-36   
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Figure 3.2. Drugs entered into clinical trails for treatment of trypanosomoasis.  
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Nifurtimox 
Nifurtimox is a 5-nitrofuran compound that was produced by Bayer and the drug is currently in 
trials for HAT therapy. It is an alternative treatment agent for cases that are resistant to 
melarsoprol. Nifurtimox is usually administered  in combination with other  antiparasitical 
agents used against T. brucei gambiense37, 38 The suggested mode of action involves the 
reduction of the nitro group to yield a radical species, which, by unknown mechanisms,  
ultimately leads to parasite death.39  
3.1.5. Combination Chemotherapy  
Combination chemotherapy is becoming the preferred methodology in today’s medicine. 
Combination drug therapy can lower dosage use when synergy exists. In some cases, this 
methodology is more effective for treatment in cases of drug resistance. For example, 
administration of suramin 15 minutes before administration of melarsoprol results in good cure 
rates in the Stage 2 mouse model. Suramin also altered the volume of distribution and 
pharmacokinetics of the experimental trypanocide megazol in mice.40 Recent clinical trials 
using a combination of eflornithine and nifurtimox  have yielded cure rates as high as 98%.38 
These studies also showed that the combinations of melarsoprol and eflornithine, or 
melarsoprol and nifurtimox were considered too toxic to pursue. However, the nifurtimox–
eflornithine combination is currently in trials due to  the  increasing failure rate of  melarsoprol 
mono therapy.38 
3.2. Leismaniasis 
Leishmaniasis is a parasitic disease transmitted by the bite of the sand fly.  According to the 
WHO report in January 2009, an estimated 12 million people are currently infected and around 
2 million new infections occur each year. The disease is prevalent in four continents and is 
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endemic in 88 countries, ranging from rainforests in Central and South America to deserts in 
West Asia. Up to 350 million people are at risk in these highly populated areas. The infection 
occurs in humans from the bite of an infected insect. However, parasites can be transferred 
among humans via blood transfusions or after sharing a needle from an infected human.41 There 
are more than 20 species and subspecies of parasites that cause leismaniasis. Patients with 
leishmaniasis demonstrate a wide range of clinical symptoms. The disease seen in humans has 
three different clinical forms; cutaneous, mucocutaneous and visceral.  
Cutaneous leishmaniasis is the most common form of the disease.42 It causes ulcers on the face, 
arms and legs. Although, the ulcers can heal spontaneously, they can also cause serious 
disability and leave severe permanent skin damage.  
In contrast, visceral leishmaniasis is the most severe form of the disease and attacks the internal 
organs.  If the patient remains untreated, this form of leishmaniasis causes death in about two 
years.43  
In mucocutaneous leishmaniasis, the patient develops partial or total destruction of the mucous 
membranes of the nose, mouth, throat cavities and surrounding tissues.44 Infections from the 
parasite occur during a blood meal on the mammalian host. The female phlebotomine sandfly 
injects the promastigotes during blood transferal from the host. Promastigotes invade host cells 
that are involved in immunity. The promastigotes transform into amastigotes and multiply by 
binary fission. In the host, amastigotes spread throughout the body and invade new cells and 
new tissues, which can cause lesions and tissue destruction. Sand flies become infected by 
receiving blood from the infected host.  Amastigotes transform into promastigotes and develop 
in the gut of the insect by binary fission while subsequently migrating to the proboscis. 
Infection is transmitted to the host with another insect bite.45 
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3.2.1. Treatment of Leishmaniasis 
The development of the chemotherapeutic agents for leishmaniasis often targets the 
intracellular amastigote form of the parasite that survives in the host and multiplies in the  
tissue macrophages.46 In many cases, patients with leishmaniasis are also co-infected with HIV. 
Treatment of these patients is often complicated and challenging.    
3.2.2. Drugs Used for Treatment of Leishmaniasis 
Pentavalent antimonial 
In 1937, a pentavalent antimonial complex, sodium stibogluconate, was the first pentavalent 
antimonial agent reported as active against leishmaniasis. These pentavalent drugs are still in 
use for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis.47 
The mechanism of drug action is not fully known. However, it is known that antimony inhibits 
the parasite’s glycotic and fatty acid oxidation activity. Thus, these drugs decrease the 
antioxidant defense mechanism and decrease energy for metabolism.48  Antimony treatment 
induces activation of important components of the intracellular signaling pathway. This action 
produces an early wave of reactive oxygen species. The reactive species are assumed  to cause 
the parasite toxicity.47 Antimonials have several disadvantages that limit their usage, including 
the requirement for up to 28 days of consecutive administration, toxicity, high cost and the 
development of significant drug resistance. 49 
Pentamidine 
Recent interest in the development of antileishmanial drugs has focused on the reduction of 
parasite drug resistance and lowering the cost. In 1952, pentamidine was shown to be effective 
against visceral and cutaneous leishmaniasis. Pentamidine is a relatively safe and effective 
first-line treatment for cutaneous leishmaniasis. Nonetheless, pentamidine was given up as a 
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second-line treatment for visceral leishmaniasis, due to toxicity. 50 However, in view of 
promising results in HIV infected leishmania patients, pentamidine might again become an 
alternative drug for treatment of co-infected patients. Studies indicate that the drug interferes 
with the mechanism of the synthesis of DNA, RNA, phospholipids and proteins.51 
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Amphotericin B 
Amphotericin B, a polyene antibiotic, has been found to be highly effective for the treatment of 
antimonial resistant L. donovani and for cases of mucocutaneous leishmaniasis that have not 
responded to antimonials.52 The drug is given by i.v. infusion and has a high toxicity. The drug 
must be administered by slow infusion over four hours. The high cost of the drug is another 
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limiting factor for use in developing countries.53  The Amphotericin B mechanism of action has 
been suggested to involve binding to the parasite surface membrane, leading to modulation of 
immune functions.54 
Miltefosine  
Miltefosine is an alkylphosphocholine that was originally developed as an anticancer drug. 
However, the drug was found to be active against leishmaniasis in the mid-1980s. The drug was 
registered in India after a Phase III trial.  A high cure rate was reported in patients with visceral 
leishmaniasis by administrating the drug orally for 28 days.55 The major limitation of 
miltefosine is teratogenicity and this excludes its use in women of childbearing age. The mode 
of action of Miltefosine is not fully understood yet. In vitro studies found  that miltefosine 
induces apoptosis-like death in the parasite.55  
Paromomycin  
Paromomycin, an aminoglycoside antibiotic, was found to be an effective antileishmanial 
product in the 1960s and the drug has been in clinical trials for both visceral leishmaniasis and 
mucocutaneous leishmaniasis.56 Phase I, II, and III studies in both visceral leishmaniasis and 
mucocutaneous leishmaniasis were successfully completed.57, 58 In bacteria, paromomycin 
inhibits protein synthesis by binding to 30S subunit ribosomes, causing misreading and 
premature termination of mRNA translation. In leishmania, paromomycin has been found to 
affect the mitochondrion.57 With the excellent efficacy, low cost, shorter duration of 
administration period and good safety profile, the drug has the potential to be a first-line drug.59 
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3.2.3. Drugs Entered into Clinical Trials 
Sitamaquine 
Sitamaquine is an orally active 8-aminoquinoline analog. The antileishmanial activity of this 
compound was first identified in the 1970s. Phase III trials for the treatment of visceral 
leishmaniasis were initiated in March 2002. Phase I and II clinical trials were completed with 
varying levels of success. Sitamaquine has been found effective for patients also infected with 
HIV.60, 61 The drug is rapidly metabolized to form desethyl and 4-CH2OH derivatives. The 
metabolized products of the drug are assumed responsible for the activity. In general, toxicity 
appears to be relatively mild, however, serious side effects such as methemglobinaemia, are 
noted in some patients.61 
3.3. Malaria 
Malaria is another parasitic, life-threatening, mosquito borne disease. According to the 2008 
World Health Organization Malaria report; there are an estimated 247 million malaria cases 
annually, and 3.3 billion people at risk of infection. Annually, malaria causes nearly a million 
deaths, the majority of whom are children under 5 years of age. The disease is endemic in 109 
countries.62 Malaria is caused by protozoan parasites of the genus Plasmodium. There are more 
than 100 species of Plasmodium known to infect animals and humans. Only five species of the 
plasmodium parasite infect humans. The most serious form of the disease is caused by 
Plasmadium falciparum. Human malaria is also caused by Plasmodium vivax, Plasmodium 
ovale, and Plasmodium malariae species, and Plasmodium knowlesi. The Anopheles gambiae 
mosquito transmits the malaria causing parasite, Plasmodium, to the host during a blood meal. 
In humans, parasites invade the liver cells where they grow and multiply, and then 
subsequently invade red blood cells. The parasite grows inside the red blood cells and destroys 
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them, releasing daughter parasites, merozoites, that continue the cycle by invading other red 
blood cells. Some parasites differentiate into sexual erythrocytic stages to male 
microgametocytes and female macrogametocytes in the blood stage. An Anopheles mosquito 
ingests the gametocytes, male (microgametocytes) and female (macrogametocytes), during a 
blood meal from an infected person. The parasites multiply in the mosquito which is known as 
the sporogonic cycle. The microgametes penetrate the macrogametes generating zygotes while 
in the mosquito's stomach. The zygotes turn into motile and elongated ookinetes and invade the 
midgut wall of the mosquito where they develop into oocysts. The oocysts grow, rupture, and 
release sporozoites and move to the mosquito's salivary glands. The sporozoites transfer to the 
new host with a mosquito bite.63  
The blood stage parasites are responsible for the clinical symptoms of the disease such as fever, 
shaking chills, headache and muscle pain. Patients who do not receive medication develop 
anemia, kidney failure, coma, and respiratory stress. 
3.3.1. Treatment of Malaria 
Most malaria symptoms are observed during the erythrocytic stage of the infection. Nearly all 
available drugs are active in the erythrocytic stage of the disease except primaquine, which is 
active in the hepatic stage of the infection. The therapy for the infected patient varies, 
depending on the infecting species. The cost of the therapy, drug resistant parasites, and the 
toxicity of the medication are the still biggest challenges remaining in the fight against the 
disease.  
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3.3.2. Drugs Used in Malaria 
Chloroquine 
A 4-aminoquinoline analog, chloroquine, is commonly used and has been an important drug for 
the treatment and the prevention of malaria for more than 50 years. This drug accumulates in 
intraerythrocytic trophozoites and prevents hemoglobin degradation.64 In addition, chloroquine 
was found to cause specific inhibition of a novel heme polymerase enzyme. However, the 
clinical usage of the drug is now  limited due to the evolution and spread of chloroquine 
resistant malaria parasites. Resistance occurs by reducing the  accumulation of the drug via an 
unidentified transmembrane protein pump in the parasite.65 
Sulfadoxine-pyrimethamine  
The sulfadoxine-pyrimethamine combination is an alternative first-line antimalarial treatment 
for use against chloroquine resistant Plasmodium falciparum.66 It is known that sulphadoxine  
competitively inhibits dihydrofolic acid synthesis by inhibiting dihydropteroate synthetase.67 In 
addition, pyrimethamine is a folic acid antagonist by binding to and reversibly inhibiting 
dihydrofolate reductase.68 The sulphadoxine and pyrimethamine combination inhibits the two 
enzymes that are involved in the biosynthesis of folinic acid in the parasite.  
Mefloquine  
The oral bioavailability and high efficacy of mefloquine make the drug an attractive alternative 
treatment for malaria.69 Mefloquine is active against the erythrocytic stages of the Plasmodium 
species. However, the drug has no effect against the exoerythrocytic stages of the parasite. The 
mechanism of the action is not fully understand though it is thought that the drug works by 
blocking the polymerization of a toxic heme released during hemoglobin proteolysis in the 
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intraerythrocytic stage of Plasmodium falciparum, causing accumulation to a level that kills the 
parasite.70 
Atovaquone-proguanil  
Atovaquone-proguanil is a fixed-dose combination tablet of two antimalarial agents and is 
highly effective for the prevention of malaria caused by Plasmodium falciparum.71 Both 
atovaquone and proguanil are active against the pre-erythrocytic stage of P. falciparum, as well 
as the erythrocytic stage of P. falciparum. The combination increases the existing inhibition 
effect of atovaquone on parasitic mitochondrial electron transport.  In addition, the drug has 
been found to be active against drug resistant strains of P. falciparum. Studies show that the 
efficacy of the atovaquone-proguanil combination is higher than mefloquine, chloroquine or 
proguanil monotherapy. Atovaquone-proguanil is generally well tolerated by both adults and 
children. The drug also showed fewer side effects than many other antimalarial agents. 72 
Primaquinine 
Primaquine has been used for preventing relapse of Plasmodium vivax and P. ovale malaria 
since the early 1950s.73 It is the only available drug  for the treatment of liver stages of 
Plasmodium vivax.74  Primaquinine can be administered orally and is rapidly absorbed from the 
GI tract. Its exact mechanism of action is not fully known, although it is believed to cause 
interference with the function of the plasmodial DNA. The major concern about the drug is 
that, if administered to glucose-6-phosphatedehydrogenase deficient patients, these patients can  
develop severe methemoglobinemia.75 
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Doxycycline  
Doxycycline is a tetracycline antibiotic. It has been used against many bacterial infections over 
the years. Tetracyclines are effective but slow acting antimalarial drugs. The drug is used as a 
prophylactic agent rather than as a treatment for malaria. The medication is not recommended 
in pediatric (under 8 years) or pregnant patients.  Its mechanism of action remains uncertain. 
Tetracyclines specifically block expression of the apicoplast genome, resulting in the 
distribution of nonfunctional apicoplasts into daughter merozoites. The loss of apicoplast 
function in the progeny of treated parasites leads to a slow but potent antimalarial effect.76 
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Artemisin  
Artemisin was isolated from sweet wormwood (Artemisia annua) in 1972 by Chinese 
scientists, and it has a  potent activity against Plasmodium falciparum.77 Artemisin is a  
sesquiterpene lactone and  widely used to treat multidrug resistant malaria.78 Studies showed 
that the mechanism of action of the drug appears to involve heme mediated decomposition. The 
endoperoxide bridge can produce carbon-centered highly reactive free radicals. The resulting 
carbon-centered free radicals may cause alkylation of heme proteins. High doses of artemisinin 
were found to be neurotoxic. The mechanism of neurotoxicity may be similar to the mechanism 
of action.79   Using the drug as a monotherapy is not recommended because parasitic resistance 
seems to be developing against artemisin. Therefore, the drug is preferred for use in 
combination therapies for malaria treatment.  
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4. Genomics Based Drug Design  
Current chemotherapies to treat parasitical diseases are expensive and many have undesirable 
side effects. In addition, many drugs used for parasitic diseases require long treatment times. 
Because of the side effects and poor bioavailability, the patients need to be under surveillance 
in an advanced health care system. It can easily be seen that this is impossible for patients who 
live in developing countries. Under these circumstances, it is urgent to develop new therapeutic 
agents against parasitical diseases.   
4.1. The Code of Life 
Deoxyribonucleic acid (DNA) exists in a variety of sizes and forms in all known living 
organisms as well as some viruses. DNA is a double stranded polymer of nucleotides, 
responsible for storing and monitoring all biological living functions. The polymer contains 
two purine bases, adenine (A), and guanine (G), and two pyrimidine bases cytosine (C), 
thymine (T). Nucleotides are linked to each other with stable phosphoester bonds. The 5’-
phosphate group of one nucleotide is joined to the 3’-hyroxyl group on the sugar to obtain 3’, 
5’-phosphodiester linkages.80 Chargaff discovered that the ratio of  adenine and thymine (A/T) 
and the ratio of guanine and cytosine (G/C) are always equal in any DNA.81 Watson and Crick 
analyzed all of the existing DNA findings and subsequently proposed that DNA intertwined to 
form a helical duplex. As such, strong hydrogen bonding between the base pairs of adenine 
with thymine and guanine with cytosine holds the two strands together. Purine and pyrimidine 
bases are stacked along the inside of the helix almost perpendicular to the sugar phosphate 
backbone which winds in an anti-parallel direction through the helix. The base pairs are stacked 
with 3.4 Å of space between each other and rotate 36o per base. Therefore, every ten base pairs 
produce one helical turn. Glycosidic bonds of the sugar rings link the bases in the helix. As 
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such, the space of the sugar-phosphate backbone results in two different grooves along the 
helix. The wide and shallow groove is called the major groove, and the narrow, deeper groove 
is called the minor groove.   
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Figure 4.1. Watson and Crick proposed DNA complementary base pairs.  
 
These two grooves twist around the surface of the double helix. The major groove   is 22 Å 
wide, filled with base pair nitrogen and oxygen atoms. The base pairs are positioned inward 
from the sugar phosphate backbone, facing the center of the double helix. In contrast, the minor 
groove is 12 Å wide and the base pairs of the minor groove are positioned outward from the 
sugar phosphate backbone towards the edges of the helix. Therefore, the edges of the bases in 
the major groove are more accessible than in the minor groove.  
Specific proteins such as transcription factors and single stranded oligonucleotides can 
recognize the specific sequences in double-stranded B-DNA.82-84 Proteins and many DNA 
intercalators use major groove interaction because major grooves have richer donor acceptor 
sites for hydrogen bonding than minor grooves. However, many ligands, small natural 
products, and even some proteins prefer to bind to the minor groove of the B-DNA.85  
There are two major types of interactions that occur between DNA and ligands; reversible and 
irreversible. Both interactions have been commonly used in therapeutic developments in 
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today`s medicine. Generally, irreversible interaction causes permanent damage to the DNA. In 
contrast, reversible ligand and DNA interactions do not cause permanent DNA damage. 
However, complex formation temporarily disturbs essential biological functions.  
4.2. DNA Groove Binders 
There are three common classes of DNA interactive agents that have been used for therapeutic 
purposes. Alkylators, in which small molecules react covalently with DNA bases, in most 
cases, the bond formation happens at guanine and adenine. Reversible binders result from 
noncovalent interactions with DNA. Strand breakers arise by reactive radical generation by a 
ligand and cause cleavage of a DNA strand. The ideal DNA interactive agent should be a 
nonpeptide, as well as sequence and site size specific.86 The design of major groove binders is 
challenging because the size of the helical gap requires large complex molecules. Some of the 
major drawbacks to consider when designing major groove binders are the synthetic process, 
delivery of the relatively large molecules, cellular transportation and cellular uptake. One such 
approach involves the use of the antisense strategy. Despite much research, antisense 
approaches for sequence specific recognition of major grooves still have a long way to before 
achieving practical use. Therefore, many research efforts currently focus on targeting the DNA 
minor groove.  
4.2.1. DNA Minor Groove Targeted Therapeutic Agents   
Over the past decades of research, X-ray crystallography, high field NMR, computational 
chemistry, and new techniques in molecular biology have provided detailed and extensive 
information about oligonucleotides, as well as their interactions. Oligonucleotides interact with 
a variety of small molecules, including;  bioinorganic species including water, and metal 
cations, small organic molecules and proteins.87  Minor groove binders generally have several 
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characteristic features, such as a curved shape, which optimizes the best fit in the helical twist, 
favorable van der Waals interactions, hydrophobic forces, and hydrogen bonding. Minor groove 
binding molecules mostly contain aromatic rings, which are connected with a single bond. 
These single bonds allow for torsional rotation of the ring systems in order to fit into the helical 
curve. The minor groove is generally narrower in the A-T rich region as opposed to the G-C 
rich region.  As a result, the A-T region provides a snugger fit for small and flat molecules. The 
location of hydrogen donors and acceptors between the base pairs plays a significant role in 
determining if minor groove binders favor the A-T region or the G-C region. In the minor 
groove of A-T regions, C2 oxygen and N3 nitrogen atoms are accessible and available for small 
molecule interaction. However, the similar location of the minor groove at G-C sequences is 
more sterically hindered, due to the additional amino group in G and the hydrogen bonding 
with C2 carbonyl oxygen. Theoretical studies of DNA showed that  the negative electrostatic 
potential of poly(dA)-poly(dT) is  much higher than the minor groove of poly(dG)-poly(dC), 
particularly due to the amino  group on C2 of guanine.88 Therefore, cationic molecules can 
show higher selectivity for the A-T rich sequence as a result of their electrostatic potential 
interactions.   
In contrast to intercalators, minor groove binding molecules generally do not induce any 
significant structural changes in the DNA nor do they significantly unwind the double helix.89   
4.2.1.1. DNA Binding Antibiotics 
a) Pyrrole-Amidine Antibiotics 
Netropsin and distamycin A are two of the well known DNA binding antibiotics which target 
the A-T sequence in double stranded DNA. Netropsin was isolated from Streptomyces 
netropsis. Distamycin A, distamycin B and C are major fermentation products of Streptomyces 
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distallicus. Both antibiotic structures contain N-methylpyrrole groups linked with amide bonds, 
which show antibacterial and antiviral activity. 
The binding of pyrrole-amidine antibiotics to DNA has been investigated using several physical 
techniques, including; UV absorption, CD, NMR, thermal melting and hydrodynamic 
measurements. Studies performed with different sequences of DNA clearly suggest that 
netropsin shows a high binding specificity to A-T base pairs, whereas no significant binding 
has been detected for G-C rich DNA .90-92   
N
H
N
O
N
NHO
O
HN
N
O
HN
NH2
NH2
+
Distamycin
N
H
N
O
NH
O
HN
N
O
HN
NH2
NH2
+
NH2
H2N
+
Netropsin
H
 
Figure 4.2. Chemical structure of Pyrrole-Amidine Antibiotics; Distamycin and Netropsin.  
 
J. W. Lown et al. successfully synthesized new derivatives of pyrrole amidine antibiotics. Their 
modification, the replacement of methylpyrrole rings with imidazole rings, changed the binding 
specificity of netropsin. Imidazole derivatives of netropsin, called lexitropsins, showed reduced 
A-T binding affinity, but increased G-C binding.  
Comparative binding experiments of distamycin A with nucleic acids in solution indicated that 
the binding results are very similar to those of netropsin. Distamycin A shows a high preference 
for A-T base pairs while almost no affinity was found for RNAs. In contrast to netropsin, 
distamycin A showed a small induced CD with G-C containing polymers.93-95  Studies 
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concluded that netropsin may act as an extended flat molecule that bridges the two strands of 
duplex DNA along the minor groove. 96  
The crystal structure analysis of netropsin suggested that bowed shape molecules provide an 
inherent geometrical fit for insertion into the minor groove.97 In addition, 1H-NMR data 
suggested that the methylpyrrole carboxamide system of distamycin adapted the same preferred 
conformation. The rotations around the bonds between pyrrole carbons and peptides provide a 
twisted shape allowing an excellent fit in the minor groove of the helix.98  Derivatives of 
distamycin were synthesized by replacing N-methylpyrrole rings with phenyl groups. The 
modification of the phenyl derivatives exhibited a reduction in binding affinity and a preference 
of A-T over G-C sequences compared to distamycin.99 
The common conclusion of molecular modeling studies was   that the A-T specificity of the 
interaction is due to hydrogen bond formation by hydrogen donating groups of the carboxamide 
system with O2 atom of thymine and N3 atoms of the adenine bases in the sequence of four to 
five A-T pairs within the minor groove. In addition, the sequence specificity of netropsin and 
distamycin are facilitated by steric inhibition of binding created by the amino group of guanine 
residues.  96, 100  
4.2.1.2. Synthetic DNA Binding Compounds 
In addition to the natural antibiotics, many chemically synthesized organic agents have shown 
promising affinity against tumors, bacterial and protozoal infections through inhibition of 
nucleic acid synthesis or by effects on the chromosomal structure.  
a) Diarylamidines 
Diarylamidines have been used for the treatment of protozoal diseases such as trypanosomiasis 
and leishmaniasis since the 1930s. In the early 1970s, a large number of diarylamidine 
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derivatives were synthesized in an effort to find more efficient antiparasitic drugs, especially 
against trypanosomes.  Compounds such as 4'-6-diamidino-2-phenylindole (DAPI), berenil, 
pentamidine and furamidine were found to be therapeutically useful agents against several 
parasitical diseases. 
DAPI showed very promising results against Trypanosome congolese.101 However, clinical use 
of DAPI has been limited due to the cyclotoxicity of the drug. The drug binds specifically to 
the AT-rich regions of double stranded DNA and has shown inhibition of DNA and RNA 
polymerase.102, 103 DAPI binding with the minor groove occurs at the ATT sequence with the 
phenyl and indole rings parallel to the groove walls. The terminal amidinium groups make a 
close interaction with C2 and N3 atoms of adenine and O2 of thymine at the A-T region on the 
helix.104 The terminal amidine groups of DAPI contribute complex stability between the 
cations and the bases through hydrogen bonds and electrostatic interactions. 105 
Another synthetic diarylamididine product, berenil, shows trypanocidal, babesicidal, and 
bactericidal activity and the drug has been used in veterinary medicine for the treatment of 
trypanosomiasis. Spectrophotometric and hydrodynamic binding studies of berenil have 
indicated that the binding affinity was selective for the minor groove in AT regions. The 
interaction of berenil with the DNA template affects the replication process. The drug’s 
biological activity has been correlated with a selective interaction with A-T regions of  
kinetoplasts within the mitochondrion.106, 107 Berenil most likely interacts in the minor groove 
by hydrogen bonding with two of the thymidine acceptor sites and by electrostatic interaction 
forces of the terminal diamidine groups.108  
Pentamidine is an aromatic dicationic analog that has been clinically used for treatment of 
infections caused by Trypanosoma brucei gambiense, Leismania donovani, and Pneumocystis 
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carinii.109 Pentamidine has been used in the treatment of P. carinii pneumonia patients who are 
HIV-positive and cannot tolerate co-trimoxazole.110  The mechanism of pentamidine action 
against P. carinii has not been elucidated. However, studies have shown that this compound 
inhibits DNA, RNA, and protein synthesis. Footprinting analysis indicated the pentamidine 
binding  preference is at the A-T rich region of the DNA minor groove,  it recognizes 
sequences containing at least five consecutive A-T base pairs.111 According to one molecular 
modeling study, researchers suggested that the terminal cationic ends of the drug could form 
hydrogen bond interactions with acceptor atoms of either adenine or thymine bases in the 
minor groove.112 
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These findings suggested that the mechanism of pentamidine is probably involved with direct 
interaction with the pathogenic genome of P. carini. Even though pentamidine is used for 
treatment of P. carinii pneumonia, the toxicity of the drug is not desirable. Therefore, usage of 
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the drug is limited to fatal infections of AIDS patients. However, the promising activity of 
pentamidine has led to the development of analogs to achieve less toxic congeners. Chemical 
modification of pentamidine has been done with different linkers and different cationic 
terminal groups. A conformationally locked derivative of pentamidine, cis-butamidine, was 
synthesized by replacement of the pentyl bridge of pentamidine with a 2-butene. The new 
analog showed increased in vitro and in vivo activity in treating P. carinii pneumonia in 
immunosuppressed rats.113 Replacement of the amidine groups of pentamidine with 
imidazoline moieties increased the anti P. carinii pneumonia activity and reduced toxicity.114 
The replacement of the triazene linker of berenil with the  five membered heterocycle furan 
gave the dicationic 2,5-diaryl furan derivative (DB 75) which is reported to be highly effective 
in in vivo studies against P. carinii in the immunosuppressed rat model.115 In addition, DB 75 
was found to be active against highly infectious parasites such as Giardia lamblia, Plasmodium 
falciparum, and Trypanosoma rhodesience.116, 117 An X-ray structure of the complex between 
DNA and DB 75 has shown that the crescent shape of the molecule matches the curvature of 
the minor groove at A-T sequences.118 The compound fits snugly to the AATT minor groove 
binding site and forms hydrogen bonds to A-T base pairs at the floor of the minor groove.115 In 
addition, biophysical examination of DB 75 also demonstrated that the drug strongly binds to 
the minor groove of DNA at A-T rich sites and weakly binds by intercalation to G-C sites of 
DNA.119 Biophysical evidence suggests a model for the biological action of DB 75 in which the 
drug binds in the DNA minor groove at A-T rich region and forms a stable complex. The 
complex formation is most likely responsible for the inhibition of one or more DNA dependant 
enzymes such as the topoisomerases. A series of DB 75 derivatives has been synthesized by 
replacing or modifying both the heterocyclic portions and the phenyl groups, as well as the 
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cationic groups. The resulting derivatives were evaluated against P. carinii infections. The 
replacement of terminal groups by cyclic amidines did not show better inhibition of 
topoisomerase isolated from G. lamblia.115 However, the introduction of different sizes of alkyl 
groups on both terminal amidino groups has shown promising activity and no overt toxicity at 
the screening dose of 10 mmol/kg/day against the immunosuppressed rat model of P.carinii. 
The X-ray structures for the derivatives, 2,5-bis[4-(N-isopropylamindino) phenyl]furan and 2,5-
bis[4-(N-cyclopropyl amidino) phenyl] furan, demonstrated the excellent fit of this class of 
compounds in the minor groove at the AATT site.115, 120, 121  In addition, studies have shown 
that these derivatives of furan amidines tend to bind to RNA by intercalation.122 The efficiency 
of these derivatives provided a lead candidate for development of more effective agents against 
P. carinii infections.  
b) Bis-benzimidazoles 
The synthetic bisbenzimidazole derivative Hoechst 33258, Pibenzimol, has been used as an 
effective DNA binding fluorophore in chromosomal banding patterns. Hoechst 33258 shows a 
fluorescence enhancement upon interaction with both A-T and G-C rich DNA. However, 
fluorescence enhancement is greater at A-T rich DNA than enhancement with G-C rich DNA. 
Hoechst 33258 is a useful tool to identify A-T regions in specific chromosome regions.123  
Hoechst 33258 has been found to be A-T selective and binds in the minor groove at four or five 
consecutive A-T base pairs. Binding was suggested to involve two bisbenzimidazole NHs 
forming a bridge with three central A-T base pairs on the floor of the minor groove between 
adjacent adenine N3 and thymine O2 atoms on opposite strands.124 Hoechst 33258 shows 
antihelmintic activity but its low potency and high toxicity have limited  usage in clinical 
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treatment.125, 126 The mechanism of cytotoxicity is not known. Hoechst 33258  easily penetrates 
cells and binds in a reversible manner to DNA and inhibits topoisomerase.127-129 
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Figure 4.4. Chemical structure of bis-benzimidazole derivatives. 
 
Switching the phenolic hydroxyl group of Hoechst 33258 from the para to the meta position 
lowers the cytotoxicity. It is assumed that the para position of the hydroxyl plays a key role for 
penetration through  cell membranes.130 Derivatives have been synthesized by alkylation of the 
phenolic hydroxyl group. These modifications produced enhanced cytotoxicity. The ready 
uptake of these compounds by the cytoplasmic and nuclear membranes, is assumed to lead to 
accumulation in the nucleus followed by inhibition of  the binding of regulatory proteins.131 
Converting the cationic bulky end on Hoechst 33258 to a planer amidine group significantly 
changes the DNA interaction affinity. Monoamidines DB 183 and DB 210, and diamidine DB 
185 was synthesized by Boykin et al. and are related to the well-known minor groove binding 
agents. Footprinting studies indicated that the synthetic compounds bind at A-T sequences in 
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the minor groove. Circular dichroism spectroscopy also showed  that the compounds bind in 
the DNA minor groove. Biosensor-surface Plasmon resonance (SPR) studies clearly showed 
that the monoamidine compounds bind to TTAA sequence in a 2:1 complex as a dimer but bind 
as a monomer to AATT. The dication, DB 185 binds to both DNA sequences as monomer 
complexes.  The binding of DB 185 at AATT is significantly stronger than binding to TTAA. 
The reason for the different binding motif at the different sequences is apparent from molecular 
dynamics simulations. These studies showed that the AATT sequence has a narrow time 
average minor groove width that is a very good receptor site for the bisbenzimidazole 
compounds. The groove is widened at the TTAA sequence and the width must be reduced to 
form a favorable monomer complex. Therefore, the monocation analogs form an antiparallel 
dimer stack and closely fits the structure of the TTAA minor groove. Another hybrid analog of 
the original Hoechst 33258 is the benzimidazole furan diamidine compound DB 293.132 The 
hybrid molecule showed a dimeric antiparallel stacking and binding motif. The stacking occurs 
preferentially at  ATGA sites.127 DB 293 analogs with either two phenyls, DB 75 or two 
benzimidazoles,  DB 270  did not show any tendency to form the stacked dimer.133 Dimer 
stacking molecules are excellent candidates for the design of gene specific targeting at minor 
groove.  
4.3. Optimal Fit to Minor Groove 
The classical approach for designing minor groove binders consists of optimizing the shape of 
the ligand to match the helical curve and twist of the groove. Any shape of the ligand that does 
not fit the curvature requirement was considered unlikely to bind. Specifically, a natural 
product, distamycin, has shown great binding affinity to the A-T minor groove of the helix. The 
natural shape of distamycin is twisted and the ligand provides a snug fit into the minor groove. 
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Replacing the N-methylpyrrole rings with phenyl groups results in a more the linear shape 
which did not bind as strongly. It was found that the naturally curved shape of distamycin 
shows strong binding affinity to the helix. This evidence strongly supports the classical 
approach for DNA binders. Tidwell et. al. examined the DNA binding properties of a series of 
bisbenzamidines, including pentamidine, by measuring changes in the thermal denaturation 
temperature.  
N
H
N
H2N
NH2+
Bisbenzimidazole diamidine
(CH2)n
N
H
N
O
H2N
H2N (CH2)n
ONH2
NH2
+
NH2
NH2
+
Bisphenyl diamidine
+
 
Figure 4.5. Structure of DNA binding compounds; bis-bezimidazole and bis-phenyl 
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The studies showed that all the analogs of bisbenzamidine compounds have a significant 
affinity for DNA and moderate specificity for AT base pairs without intercalation.  The 
derivatives of pentamidine, with an odd number of methylene linkages between the 
benzamidine rings, had a stronger binding affinity for the minor groove than  derivatives with 
an even number linkage. Switching the cationic ends to the meta position resulted in lower 
polynucleotide affinity. All these findings suggested that the shape of the molecules is 
important for DNA binding affinity. Modeling studies demonstrated the correlation between the 
DNA binding and the radius of the curvature of molecular mechanic models of the molecules. 
Later, similar studies of a series of bis-amidinobenzimidazo1es and bis-amidinoindo1es with 
varied linking chains reported similar results. The analysis of the shape of the molecules is 
consistent with this mode of nucleic acid binding. Analogs, with an even number of methylene 
linkages with the benzimidazole rings have a higher affinity for DNA than those with an odd 
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numbers. Molecular modeling studies suggested that the shape of the molecule, as a function of 
chain length, affects the strength of nucleic acid binding. In addition, hydrogen bonding from 
the imidazole nitrogens and electronic effects from the cationic substituents contribute to the 
nucleic acid affinity.134 
Another interesting example of the crescent shape ligands are furamidine derivatives. 
Furamidine (DB 75) has significantly better activity against a number of parasites with lower 
toxicity than pentamidine. Modification of the parent phenyl-furan phenyl diamidine to a 
phenyl-thiophene-benzimidazole derivative yielded an analogue which showed a 10-fold 
increase in affinity for the minor groove at AT region. An X-ray investigation of the derivatives 
indicated a small bond angle difference between the C-S-C angle of thiophene and the C-O-C 
angle of furan leads to a better fit for the terminal ends of the benzimidazole compounds at the 
floor of the groove. This effect is thought to cause the significant difference in binding 
affinity.135 
All of these examples, in addition to other studies not summarized in this chapter, have 
confirmed that the shape of the ligand is an important factor in strong binding.  
4.4. Non-Classical DNA Minor Groove Binders  
Synthetic compounds, which fit into a classic isohelical approach, have shown strong binding 
to the DNA minor groove. Compounds that are too curved, or too linear have shown poor 
minor groove binding affinity. The crescent shape of the ligands has been viewed as important 
in the design of new therapeutic agents, but it is not the only factor for strong binding. Several 
compounds that do not fit into the classical concept have showed unexpected DNA binding 
results. Several synthetic dicationic linear, or close to linear shaped ligands have been shown to 
bind extremely strongly to the minor groove in A-T rich regions. In a contrast, the highly 
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curved molecule, bisamidino diphenylether benzimidazole RT 29, was shown to bind to the 
DNA minor groove stronger than many ligands that were designed following the isohelical 
binding criteria.136, 137 The linear shaped compound, CGP40215A is not complementary to the 
curve of the DNA groove. However, the ligand exhibited a high binding affinity in comparison 
to curved diamidine molecules.  
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The positively charged amidine groups at the ends of the CGP40215A and the proton donor 
amino groups on the linker interact with the DNA bases. Both the X-ray and molecular 
dynamics studies indicated that water molecules act like a mediator to form hydrogen bonds 
between the ligand and the DNA.111  Complementary results were obtained by investigating the 
linear DB 921 and its curved derivative DB 911. DB 921 is a near linear dicationic 
benzimidazole-biphenyl molecule while DB 911 has the classical crescent shape. The central 
meta substituted phenyl gives the compound a shape similar to known crescent shaped minor 
groove binding compounds. The experimental results were surprising; DB 921 is a dicationic 
near linear compound that does not have the appropriate radius of curvature to match the 
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groove shape. Therefore, it was expected that DB 911 should be a more effective minor groove 
binder than DB 921. However, studies indicated that DB 921 not only binds in the groove but 
that it also has a significantly higher binding constant (2.9 × 108 M-1, vs 2.1 × 107 M-1 for DB 
911). The X-ray structure of the DB 921 complex shows that an induced fit structural change in 
DB 921 reduces the twist of the biphenyl to complement the groove. This change places the 
functional groups in position to interact with DNA bases at the floor of the minor groove. A 
water molecule forms hydrogen bonds between the phenylamidine and the groove bases. DB 
921 and a water molecule complete a curved binding module that is complementary to the 
minor groove and provides a number of strong hydrogen bonding interactions that are not 
possible with DB 911.138 
The crescent shape of the ligand is important for the optimal fit of many natural and synthetic 
compounds within the minor groove of the helix. However, new findings also suggest that the 
traditional requirement of a compound’s curvature shape for DNA minor groove complex 
formation needs to be reevaluated. As such, the role of water should be considered in the 
development of the new DNA binders.  
4.5. Conclusions 
The genetic diversity of all living forms is a very attractive target for the development of new 
therapeutic agents.  In addition, more in depth understanding of DNA and its interactions are 
being utilized to develop methodologies to design and develop future therapeutics agents. For 
many biological and biophysical reasons, the DNA minor groove provides a useful target for 
ligand interactions. Therefore, the minor groove of the helix is a potential target for many drugs 
in modern medicine. Even though gene targeting methodology is a powerful approach for 
finding a cure at the molecular level, researchers still have many challenges to overcome, 
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including;  gene sequence specificity, cytotoxicity, and delivering the drug to the genes. In this 
review, we have only summarized results for a few of the important natural and synthetic DNA 
minor groove binding compounds. Of these, the majority noncovalently bind to the DNA minor 
groove at AT rich sequences without intercalation. Because of their sequence specific 
recognition in the minor groove of the helix, these ligands hold potential for developing new 
gene specific reagents. Studies with these compounds indicate that the binding affinity for  the 
ligand and nucleic acid complexes depend on several factors, including a complementary shape 
of the ligand for minor groove. In many cases, the crescent shape of the drug is extremely 
important for fit within the minor groove. However, recent results have shown that high 
binding affinity is not limited to crescent shape molecules. In fact, water can join with linear 
molecules to bind strongly to the DNA minor groove. Extensive efforts are still underway in 
hopes of developing gene specific agents, or the “magic bullet,” to cure existing diseases.  
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5. Design and Synthesis of Linear Diamidine Molecules as Antiparasitic Agents 
Abstract 
Diamidine compounds, DNA minor groove binders, have been used as treatment for many 
different diseases for over half a century. Typically, DNA minor groove binders need to be 
crescent shaped to create a complimentary fit in the groove. However, recent studies indicate 
that linear dicationic molecules can show a strong binding affinity with DNA and show 
promising antiparasitic activity in in vivo. These linear molecules can bind as strongly to DNA 
as crescent shaped dicationic compounds. To further evaluate the linear dicationic molecules, a 
small series of diamidine arylacetylene derivatives were synthesized and two of them were 
tested against Trypanosoma brucei rhodesiense and Plasmodium falciparum. However, the 
examined diamidine derivatives were found to have only moderate in vitro activity.  
5.1. Introduction 
DNA carries the genetic information about living organisms and is intricately involved in many 
essential biological and pathological processes. The clarification of the DNA structure by 
Watson and Crick in 1953 opened a new era in molecular biology.  As DNA studies have 
progressed, increased understanding of its structure and role in living cells has made 
oligonucelotides a promising target for design of therapeutic reagents.  
Proteins, natural products, and synthetic cationic products can show strong reversible and 
irreversible interactions with double helix grooves. 1  Aromatic cations have shown strong and 
reversible binding affinities at DNA minor grooves. 2 These interactions can be used to develop 
new therapies.   Diamidine compounds such as pentamidine, propamidine, and berenil have 
been successfully used to treat infections caused by parasites and fungi. 3  Pentamidine is used 
in the initial stage of HAT, as well as a secondary treatment for AIDS related P. jiroveci 
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pneumonia. 4  Studies show that biological activities of aromatic diamidine compounds have 
been correlated with their interaction with the DNA minor groove at AT sequences. 1  
H2N
NH2
O O
NH2
NH2 ++
H2N
NH2
O O
NH2
NH2
++
H2N
NH2
N
N
N
NH2
NH2 ++
H
Pentamidine Propamidine
Berenil  
Figure 5.1. Structure of diamidine compounds that have been successfully used to treat 
infections caused by parasites and fungi.  
 
The typical interactions of molecules which exhibit strong DNA minor groove binding, are as 
follows: H-bonding, van der Walls interactions, complementary charge and complementary 
shape. A curved shaped molecule provides the optimal fit to the helical curve in DNA. In 
support of the optimal fit theory, many crescent shaped diamidine compounds show strong 
binding affinity in A-T rich sequences such as pentamidine, furamidine and their analogs. 
However, recent studies indicate that near linear diamidine compounds also can show quite a 
strong interaction with minor groove at A-T sites. 5  
Unexpectedly, DNA binding studies with the linear diamidine compound CGP 40215 showed 
that it binds quite strongly to A-T sequences. However, it was commonly believed that the 
ligand should have a curved shape to create a perfect match to the helical turn in the minor 
grove. The crystal structure of the complex of CGP 40215 at a AATT binding site provided an 
explanation for the unexpected  binding capability of the linear compound. 
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Figure 5.2. Structure of dicationic aryldiamidines which shown unusual binding affinity with 
duble helix. 
 
A single water molecule is able to form a direct contact between the cationic amidine ends of 
the compound and the A-T base pair groups at the floor of the minor groove. CGP 40215 
completes the curved shape by interaction with water in the DNA-ligand complex. A similar 
observation was recorded during the investigation of biphenylbenzimidazole derivatives. DB 
911 has a central meta-substituted phenyl that gives it a classical curved shape that binds to the 
DNA minor groove with a strong affinity. On the other hand, DB 921 has a central para-
substituted phenyl that has a much more linear shape, which obviously does not match the 
curvature of the DNA minor groove. However, binding studies have shown that DB 921, even 
though it is near linear, has an almost 10 fold higher binding affinity to the DNA minor groove 
at A-T sequences. Compound to CGP 40215 and DB 921 interact with a water molecule in the 
complex to form a complementary module.6 In addition to the strong binding affinity, many 
other linear shaped dicationic compounds show promising in vivo activity against parasites in 
animal models.7  
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Based on this previous knowledge, we have designed derivatives of linear diamidine 
compounds that may target the AT rich minor groove and may serve as a therapeutic agents, 
Figure 5.3. We decided to make linear diamidines which are symmetric, These molecules may 
be viewed as a a simplification of DB 921, in which the benzimidazole group is removed. The 
designed molecules (Figure 5.3) are some what longer than DB 921, and are devoid of 
hydrogen bond donors other than the amidine units. In this line, a small series of dicationic 
amidinophenylethynyl benzene derivatives were synthesized in order to evaluate their DNA 
binding and biological activities.   
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Figure 5.3. Chemical structures of bis-amidinophenylethynyl benzene derivatives.   
 
5.2. Result and Discussion 
5.2.1. Chemistry 
The target diamidino arylacetylenes 1-5  were obtained from the respective bis-nitriles 14-18 
by direct reaction using lithium trimethylsilylamide, Scheme 5.1. The bis-nitriles intermediates 
were synthesized by palladium catalyzed Sonogashira coupling reactions  of the respective 
bromo arylnitriles 9-13  and diethynylbenzene 8. The syntheses of  the bis-nitriles 14-18 
108 
 
 
require diethynylbenzene 8  as a common precursor. Diethynylbenzene 8 was conveniently 
achieved in two steps; starting with a Sonogashira coupling between diiodobenzene 6 and 
trimethylsilylacetylene followed by deprotection of trimethylsilyl- under basic conditions to 
furnish diethynylbenzene 8.  
I I
i
Si Si
ii
6 7 8
X Y
NC Br
R1 R2
iii
X Y
NC
R1 R2
Y X
CN
R2 R1
14-18
ii
X Y
R1 R2
Y X
R2 R1
1-5
HN
H2N
NH
NH2
                   X       Y      R1     R2
  9, 14, 1;   CH     CH    H      H
10, 15, 2;   CH      N      H      H
11, 16, 3;    N      CH     H      H
12, 17, 4;   CH    CH     F       H
13, 18, 5;   CH    CH     H       F
9-13
  
Scheme 5.1. Synthesis of biamidino arylacetylene derivatives. 
Reagents and conditions: i) (CH3)3SiCCH, Pd(PPh3)3Cl2, CuI, PPh3, diethylamine, DMF, 120 o 
C, 68%; ii)  LiOH, MeOH, 90%; iii) 9-13, 1,4-diethynylbenzene 8, Pd(PPh3)4, CuI, 
diethylamine, DMF, 120 o C, 24-38%; iv) LiN(TMS)2,  THF, rt., MeOH, HCl, 75-92%.  
 
The bis-nitrile synthesis route was quite straightforward. However, the coupling reactions gave 
undesired mono, homo, and self-coupling products and poor yields of the desired compounds, 
eventhough the reactions were carefully conducted in an inert atmosphere, using a well-dried 
apparatus, reagents, and solvents. Despite many experimental trials with different conditions, 
the best yield of the desired products was 38%. 
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Under these circumstances, we designed a different synthetic approach for obtaining the bis-
nitriles by Sonogashira coupling between arylacetylene and diiodoarene, Scheme 5.2. First, 4-
ethynylbenzonitrile 20 was synthesized from 4-bromobenzonitrile 9 with similar reaction 
sequences as described above for synthesis of 8. Sonogashira coupling of 20 and 1,4-
diiodobenzene 6 gave the desired product 1,4-bis-(4-cyanophenylethynyl)benzene 14, however, 
only in a 42% yield. 
 
NC Br SiNC NC
9 19 20
i ii
iii
X Y
NC
R1 R2
Y X
CN
R2 R1
14  
Scheme 5.2. An alternative synthesis route of bis-nitrile. 
Reagents and conditions: i) (CH3)3SiCCH, Pd(PPh3)3Cl2, CuI, PPh3, diethylamine, DMF, 120 o 
C, 68%; ii)  LiOH, MeOH, 89%; iii) 4-ethynylbenzonitrile 20, 1,4-diiodobenzene, CuI, PPh3, 
diethylamine, DMF, 120 o C, 42%.  
 
The yield was only slightly  improved compared to first synthesis approach. The convenience 
of direct use of commercially available bromo arylnitriles in Sonogashira coupling with 
diethynylbenzene lead us to use the first route, Scheme 5.1.  
110 
 
 
5.2.2. Biology 
Aromatic diamidines are well known cationic molecules that have a strong and reversible 
interaction with DNA. Recent work has shown that linear and near linear molecules exhibit 
excellent biological activity against trypanosomes.8  The mechanism of action for 
antitrypanosomal activity has been suggested to involve the inhibition of DNA dependent 
enzymes or direct inhibition of transcription.9, 10  
 
Table 5.1. DNA affinities and in vitro antiprotozoan data for linear dications.  
Compound 
ΔTma  
(o C) 
  
T.b.r. b  
IC50  
(µM) 
P.f. b   
IC50  
(µM) 
cytotoxicityc  
IC50  
(µM) 
Pentamidine 12.6  0.0022 NA 2.1 
Furamidine 25.0  0.0045  0.0155 6.4 
DB 921 28.0  0.0077  0.0005           17.0 
DB 1762 (1)   4.0  0.812  0.166 7.4 
DB 1914 (2) NA  0.441  0.22           99.6 
 
a Poly(d(A-T)2 in MES10 buffer; ratio compound/DNA is 0.3. b The T.b.r.(Trypanosoma brucei rhodesiense) strain 
was STIB900, and the P. f. (Plasmodiumfalciparum) strain was K1. cCytotoxicity was evaluated using cultured L6 
rat myoblast cells using the same assay procedure for T. b. r. 
 
The biological activity of newly synthesized linear dicationic compounds; DB 1762, 1 and DB 
1914, 2 was evaluated against T.b.r. and P.f.  However, the new compounds were much less 
active than standard compounds in Table 5.1. DB 1762 and DB 1914 gave IC50 values against 
T.b.r of 0.812 and 0.441 µM, respectively, compared to values of the standards at 2 to 7 nM, 
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Table 5.1. The activity of DB 1762 and DB 1914 agaist P.f. (IC50 value of 0.666 and 0.221 µM) 
was also much less than the standard (0.0155 µM). The  ΔTm value of DB 1762 was found 
significanly less than standard compounds. Most likely, DB 1762 does not bind to the DNA 
with a strong affinity. The moderate bioactivity maybe due to low DNA affinity, poor cellular 
up take or a combination of both. We are awaiting data on the remaining analogs which are 
structurally quite similar. Nevertheless, it is unlikely that further studies on these analogues will 
be performed.  
5.3. Conclusions 
Diarylamidines have been used as chemotherapeutic agents for infections caused by parasites 
since the middle of the 20th century. Their mechanisms of action against the microbes are not 
well understood. Along with the great activity of these dicationic compounds, they also exhibit 
toxic effects. Studies to overcome these major drawbacks are continuing. 
5.4. Methods and Materials 
5.4.1. Synthesis  
All moisture and air sensitive reactions were carried out in glassware that was oven dried 
overnight and under dry nitrogen (passed through drying agents). Commercially supplied 
chemicals and reagents were used without additional purification. Ether and THF were distilled 
from Na and benzophenone. Triethylamine (CaH2) and ethanol (Mg/I2) were distilled from the 
indicated drying agents. Ethanolic HCl solutions were prepared from fresh distilled dry ethanol 
that was treated with dry HCl gas for 10-15 min at ice bath temperature. Anhydrous DMF was 
purchased from Aldrich. TLC analysis was carried out on silica gel 60 F254 coated aluminum 
sheets and detection was  with two wavelengths of UV light. Column chromatography was 
performed with silica gel (flash 32-63 nm), from Dynamic Adsorbents Inc, in Norcross, GA. 
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Melting points were recorded using a Mel-Temp 3.0 capillary melting point apparatus and are 
uncorrected. Mass spectrometry analyses were performed by the Mass Spectrometry Facilities 
of Georgia State University by chemical ionization under conditions which gave the protonated 
species M+1. Elemental analyses were performed by Atlantic Microlab, Atlanta, GA. 1H and 
13C NMR spectra were recorded a Bruker 400 MHz instrument. Chemical shifts (δ) are given in 
ppm relative to TMS (0 ppm), DMSO (2.49 ppm), CHCl3 (7.24 ppm) or MeOH (3.31 ppm) for 
1H spectra and TMS (0 ppm), DMSO (39.52 ppm), CHCl3 (77.16 ppm) or MeOH (49.00 ppm) 
for 13C spectra.  
5.4.2. In Vitro Assays  
In vitro efficacy and cyctotoxcity studies were performed at the Swiss Tropical Institute in 
Basel, Switzerland under the direction of Professor Reto Brun according to published 
procedures ( T.b.r.,11 P.f.12, 13 and cyctotoxcity14). Tm measurments were performed at Georgia 
State University, under the direction of Professor David Wilson. We are grateful for being 
provided these data by Professor Brun and Professor Wilson.   
5.4.3. Synthetic Procedures  
1,4-Bis-trimethylsilanylethynylbenzene (7). 
 A mixture of 1,4-diiodobenzene 6 (2 g, 6.0  mmol), Pd(PPh3)Cl2 (420 mg, 0. 6 mmol), CuI (40 
mg, 0. 6 mmol), triphenylphosphine (630 mg, 2.4 mmol) was degassed and flushed three times 
with dry nitrogen. Trimethylsilylacetylene (2.5 mL, 18 mmol), dry diethylamine (3 mL), and   
dry DMF (3 mL) was injected into a pressure glass vial and sealed with a Teflon septum. The 
mixture was stirred at 120 ºC for 2 hours. The solvent was removed under reduced pressure to 
give a residue, which was dissolved in ethyl acetate (50 mL) and washed with 5% NaHCO3 (2 
× 20 mL). The organic layer was dried over Na2SO4. The organic layer was filtered, the filtrate 
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was concentrated under reduced pressure  and the residue was purified with column 
chromatography eluting with hexenes /ethylacetate (5:1) to give 7 as a white solid (1.1 g, 68%); 
mp: 120-121 oC; (lit15 mp: 117-119 oC).  1H NMR (CDCl3): δ 7.38 (s, 4H), 0.24 (s, 18H). 13C 
NMR (100 MHz, CDCl3): δ 131.9, 123.4, 104.81, 96.5, 0.25  ppm.  
1,4-Diethynylbenzene (8). 
1,4-Bis-(trimethylsilanylethynyl)benzene 7  (1.0 g, 3.7 mmol) and LiOH (0.2 g 8.3 mmol) were 
dissolved in  methanol (5 mL) and dicholoromethane (5 mL), and the mixture was stirred at 
room temperature overnight. The solvent was removed under reduced pressure and the residue 
was dissolved in ethyl acetate (150 mL) and washed with 5% NaHCO3 (3 ×20 mL). The 
organic layer was dried over Na2SO4, filtrered and the filtrate was concentrated under reduced 
pressure. The solid was purified with column chromatography by eluting with hexanes/ethyl 
acetate (7:1) to give 8 as a white solid ( 420 mg, 90%); mp: 97-98 oC; (lit16 mp: 96-97 oC). 1H 
NMR (CDCl3): δ 7.42 (s, 4H), 3.16 (s,  2H). 13C NMR (100 MHz, CDCl3): δ 132.1, 122.7, 
83.22, 79.33 ppm.  
4-[(Trimethylsilyl)ethynyl]benzonitrile (19). 
19 was synthesized by following  a similar  procedure as that used  for the synthesis of 7, 
starting with 4-bromobenzonitrile 9. The crude product was purified with column 
chromatography by eluting with hexanes/ethyl acetate (4:1) to give 10 as a white solid (62%); 
mp: 96-97 oC; (lit17 mp: 96-98 oC). 1H NMR (CDCl3): δ 7.58 (d, J= 8.4, 2H), 7.52 (d, J= 8.4, 
2H) 0.26 (s,  9H). 13C NMR (100 MHz, CDCl3): δ 132.4, 131.9, 127.9,118.3, 102.9, 99.5, -0.27 
ppm. 
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4-Ethynylbenzonitrile (20). 
20 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-
diethynylbenzene 8, starting with compound 19. The crude product was purified with column 
chromatography by eluting with hexanes/ethyl acetate (3:1) to give 20 as a white solid (89%); 
mp: 96-97 oC; (lit17 mp: 96-98 oC). 1H NMR (CDCl3): δ 7.62 (d, J= 8.4, 2H), 7.57 (d, J= 8.4, 
2H), 3.30 (s,  1H). 13C NMR (100 MHz, CDCl3): δ 132.6, 132.0, 127.9,118.2, 112.3, 81.87, 
81.57 ppm.  
1,4-Bis-(4-cyanophenylethynyl)benzene (14). 
A mixture of 4-bromobenzonitrile 9 (2 g, 10.9 mmol), Pd(PPh3)Cl2 (379 mg, 0.54 mmol), CuI 
(140 mg, 2.17 mmol), triphenylphosphine (141 mg, 0.54 mmol), 1,4-diethynylbenzene 8 (688 
mg, 5.4 mmol) was degased in a round bottom flask and flushed with dry nitrogen three times. 
Dry triethylamine (5 mL) and dimethylformamide (10  mL ) was injected into the mixture. The 
reaction mixture was stirred at 110-120 ºC overnight in a nitrogen atmosphere. The solvent was 
removed in vacuo to give a residue, which was dissolved in dichloromethane (250 mL) and the 
organic layer was washed with 1 N NH4Cl (3×50 mL). The organic layer was dried over 
MgSO4 and filtered.  The filtrate was treated with charcoal and was allowed to heat at reflux 
for an hour. The solvent was filtered through celite while hot. The filtrate was concentrated 
under reduced pressure and the residue was crystallized in DMF (3 mL), the solid was washed 
with dry ether to give a white solid in (680 mg, 37%); mp: 278-280 oC . 1H NMR (400 MHz, 
CDCl3): δ 7.65 (d, J= 8.8, 4H), 7.61 (d, J= 8.8, 4H), 7.54 (s, 4H).  
Alternative synthesis of 1,4-bis-(4-cyanophenylethynyl)benzene (14).  
A mixture of 4-ethynylbenzonitrile 20 (2 g, 15.7 mmol), Pd(PPh3)Cl2 (273 mg, 0.4 mmol), CuI 
(25 mg, 0.4 mmol), 1,4-diiodobenzene 6 (2.6 g, 7.8 mmol) was degased in a round bottom flask 
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and flushed with dry nitrogen three times. Dry triethylamine (7 mL) and anhydrous  
dimethylformamide (15  mL ) was injected into the mixture. The reaction mixture was bubbled 
with nitrogen for 15 min, then stirred at 110-120 ºC for 32 hours in a nitrogen atmosphere. The 
solvent was removed under reduced pressure, and the yellow residue was dissolved in 
dichloromethane (400 mL) and the organic layer was washed with 1 N NH4Cl (4×100 mL). The 
organic layer was dried over MgSO4 and filtered.  The filtrate was treated with charcoal and 
was allowed to heat at reflux for an hour. The organic solvent was filtered through celite while 
hot. The filtrate was concentrated under reduced pressure and the residue was crystallized from 
DMF (2 mL) and ether (2 mL) mixture. The solid was washed with dry ether to give a white 
solid in (1.5 g, 42%); mp: 278-281 oC . 1H NMR (400 MHz, d6-DMSO): δ 7.90 (d, J= 8.4, 4H), 
7.76 (d, J= 8.4, 4H), 7.67 (s,  4H). Analysis calculated for C24H12N2-0.5H2O: C, 85.44; H, 3.88; 
N, 8.30; found: C, 85.90; H, 3.68; N, 8.30.  
1,4-Bis-(5-cyanopyridyl-2ylethynyl) benzene (15).  
 15 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-bis-
(4-cyanophenylethynyl)benzene 14 starting with 6-bromonicotinonitrile 10 to yield  15 as a 
pale yellow solid (35%); mp: 344-347 oC. 1H NMR (400 MHz, d6-DMSO): δ 9. 04 (d, J= 1.2, 
2H), 8.36 (dd, J1= 2.0, J2= 8.0, 2H), 7.87 (d, J= 8.4, 2H), 7.76 (s,  4H). Analysis calculated for 
C22H10N4-0.25H2O: C, 78.91; H, 3.16; N, 16.73; found: C, 78.95; H, 3.11; N, 16.75.  
1,4-Bis-(2-cyanopyridyl-5ylethynyl)benzene (16). 
16 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-bis-
(4-cyanophenylethynyl)benzene 14 starting with 5-bromo-2-cyanopyridine 11 to  yield  16 as a 
pale yellow solid (25%) ; mp: 344-347 oC. 1H NMR (400 MHz, d6-DMSO): δ 8.94 (d, J= 2, 
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2H), 8.24 (dd, J1= 2.0, J2= 8.0, 2H), 8.10 (d, J= 8.0, 2H), 7.73 (s,  4H). Analysis calculated for 
C22H10N4-0.9H2O: C, 76.24; H, 3.32; N, 16.16; found: C, 76.55; H, 3.32; N, 15.94.  
1,4-Bis-(2-fluoro-4-cyanophenylethynyl)benzene (17). 
17 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-bis-
(4-cyanophenylethynyl)benzene 14 starting with 4-bromo-3-fluorobenzonitrile 12 to  yield  17 
as a pale yellow solid (28%) ; mp: 240-243 oC. 1H NMR (400 MHz, CDCl3): δ 7.66-7.56 . (m, 
6H), 7.48-7.43 (m, 4H). Analysis calculated for C24H10F2N2-0.8C4H10O: C, 77.11; H, 4.28; N, 
6.61; found: C, 78.54; H, 4.24; N, 5.98.  
1,4-Bis-(3-fluoro-4-cyanophenylethynyl)benzene (18). 
 18 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-bis-
(4-cyanophenylethynyl)benzene 14 starting with 4-bromo-2-fluorobenzonitrile 13to  yield  13e 
as a pale yellow solid (24%) ; mp: 237-239 oC. 1H NMR (400 MHz, CDCl3): δ 7.65-7.52 . (m, 
6H), 7.43-7.28 (m, 4H). Analysis calculated for C24H10F2N2: C, 79.12; H, 2.77; N, 7.69; found: 
C, 79.86; H, 2.80; N, 6.95.  
1,4-Bis-(4-amidinophenylethynyl)benzene hydrochloride salt (1). 
1,4-Bis-(4-cyanophenylethynyl)benzene 14 (100 mg, 0.3 mmol) was placed in an oven dried 50 
mL round bottom flask and sealed with a rubber septum. The flask was degassed and flushed 
with dry nitrogen. Then, fresh distilled THF (3 mL) was injected into the flask with a syringe 
under a nitrogen atmosphere. The solution was cooled to 0 oC in an ice bath and then was 
treated with lithium trimethylsilyamide (1 M in THF) (2 mL). The reaction mixture was stirred 
at room temperature overnight. The mixture was cooled in an ice bath and was treated with 
ethanol-HCl (1 mL). The mixture was stirred for 2 hours and diluted with ether. The  precipitate 
was filtered and washed with generous amounts of ether to yield a white solid. The solid was 
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suspended in a methanol and water mixture. A 10% NaOH solution was added to the 
suspension until pH of 10 was reached and then stirred for an hour. The precipitate was filtered 
and dried under reduced pressure overnight. The solid was suspended in dry MeOH (10 mL) 
and cooled to 0 oC in an ice bath and  ethanol-HCl (1 mL) was added. The mixture was stirred 
overnight, diluted with dry ether and filtered.  Next, it was  washed with dry ether to produce a 
white solid (80 mg, 61%); mp: 314-317 oC. 1H NMR (400 MHz, d6-DMSO): δ 9.33 (br, 8H, 
NH), 7.91 (d, J= 8.0 Hz, 4H), 7.83 (d, J= 8.0 Hz, 4H), 7.70 (s. 4H). ESI-MS: m/z calculated 
for C24H18N4:362.4; found: 363.3 (M+1). Analysis calculated for C24H18N4-2HCl-2H2O: C, 
61.15; H, 4.88; N, 11.89; found: C, 61.21; H, 4.63; N, 11.52. 
1,4-Bis-(5-amidinopyridyl-2ylethynyl)benzene hydrochloride salt (2).  
1,4-Bis-(5-amidinopyridyl-2ylethynyl)benzene hydrochloride salt 2 was synthesized by 
following a similar  procedure as that used for the synthesis of 1,4-bis-(4-amidinophenyl 
ethynyl) benzene hydrochloride salt 1 starting with 1,4-Bis-(5-cyanopyridyl-2ylethynyl) 
benzene  15 to  yield  2 as a white solid (64%) ; mp: 324-326 oC. 1H NMR (400 MHz, d6-
DMSO): δ 9.66-9.39 (br d, 8H, NH), 9.03(s, 2H), 8.31 (d, J= 8.4 Hz, 2H),  7.95 (d, J= 8.0 Hz, 
2H), 7.78 (s, 4H). ESI-MS: m/z calculated for C22H16N6: 364.1; found: 365.2 (M+1).Analysis 
calculated for C22H16N6-4HCl-1.3H2O-C4H10O: C, 49.92; H, 4.52; N, 15.32; found: C, 49.77; 
H, 4.11; N, 15.09.  
1,4-Bis-(2-amidinopyridyl-5ylethynyl)-benzene hydrochloride salt (3). 
1,4-Bis-(2-amidinopyridyl-5ylethynyl)-benzene hydrochloride salt 3 was synthesized by 
following a similar  procedure as that used for the synthesis of 1 starting with 1,4-Bis-(2-
cyanopyridyl-5ylethynyl)benzene 16 to yield  3 as a white solid (61%) ; mp: >350 oC. 1H NMR 
(400 MHz, d6-DMSO): δ 9.70-9.52 (br d, 8H, NH), 9.02 (s, 2H), 8.40 (s, 4H), 7.76 (s, 4H). 
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ESI-MS: m/z calculated for C22H16N6: 364.1; found: 365.2 (M+1). Analysis calculated for 
C22H16N6-4HCl-0.2H2O-1.3C4H10O: C, 53.53; H, 5.51; N, 13.77; found: C, 53.34; H, 5.29; N, 
13.74.  
1,4-Bis-(4-amidino-2-fluorophenylethynyl)benzene hydrochloride salt (4). 
4 was synthesized by following a similar  procedure as that used for the synthesis of 1,4-bis-(4-
amidinophenylethynyl)benzene hydrochloride salt 1 starting with 1,4-bis-(2-fluoro-4-
cyanophenylethynyl)benzene 17 to  yield  4 as a white solid (58%) ; mp: >350 oC. 1H NMR 
(400 MHz, d6-DMSO): δ 9.57-9.42 (br d, 8H, NH), 7.78-7.74 (m, 4H), 7.71 (s, 4H), 7.70-7.63 
(m, 2H). ESI-MS: m/z calculated for C24H16F2N4: 398.4; found: 399.3 (M+1). Analysis 
calculated for C24H16F2N4-2HCl-0.5H2O: C, 60.01; H, 3.98; N, 11.66; found: C, 60.08; H, 3.97; 
N, 10.04.  
1,4-Bis-(4-amidino-3-fluorophenylethynyl)benzene hydrochloride salt (5). 
1,4-Bis-(4-amidino-3-fluorophenylethynyl)benzene hydrochloride salt 5 was synthesized by 
following a similar  procedure used for the synthesis of 1 starting with 1,4-bis-(3-fluoro-4-
cyanophenylethynyl)benzene 18 to  yield  5 as a white solid (52%) ; mp: >350 oC. 1H NMR 
(400 MHz, d6-DMSO): δ 9.57-9.42 (br d, 8H, NH), 7.79-7.76 (m, 4H), 7.71 (s, 4H), 7.65-7.63 
(m, 2H). ESI-MS: m/z calculated for C24H16F2N4: 398.4; found: 399.3 (M+1). Analysis 
calculated for C24H16F2N4-2HCl-0.25H2O-0.41C4H10O: C, 60.83; H, 4.48; N, 11.06; found: C, 
61.15; H, 3.98; N, 10.61.  
119 
 
 
References 
1. Chaires, J. B.; Ren, J.; Hamelberg, D.; Kumar, A.; Pandya, V.; Boykin, D. W.; Wilson, 
W. D. Structural Selectivity of Aromatic Diamidines. J. Med. Chem. 2004, 47, 5729-5742. 
2. Wang, L.; Bailly, C.; Kumar, A.; Ding, D.; Bajic, M.; Boykin, D. W.; Wilson, W. D. 
Specific molecular recognition of mixed nucleic acid sequences: An aromatic dication that 
binds in the DNA minor groove as a dimer. Proceedings of the National Academy of Sciences 
2000, 97, 12-16. 
3. Crowell, A. L.; Stephens, C. E.; Kumar, A.; Boykin, D. W.; Secor, W. E. Activities of 
Dicationic Compounds against Trichomonas vaginalis. Antimicrob. Agents Chemother. 2004, 
48, 3602-3605. 
4. Soeiro, M. N.; De Souza, E. M.; Stephens, C. E.; Boykin, D. W. Aromatic diamidines as 
antiparasitic agents. Expert Opinion on Investigational Drugs 2005, 14, 957-972. 
5. Nguyen, B.; Lee, M. P. H.; Hamelberg, D.; Joubert, A.; Bailly, C.; Brun, R.; Neidle, S.; 
Wilson, W. D. Strong Binding in the DNA Minor Groove by an Aromatic Diamidine with a 
Shape That Does Not Match the Curvature of the Groove. J. Am. Chem. Soc. 2002, 124, 13680-
13681. 
6. Miao, Y.; Lee, M. P. H.; Parkinson, G. N.; Batista-Parra, A.; Ismail, M. A.; Neidle, S.; 
Boykin, D. W.; Wilson, W. D. Out-of-Shape DNA Minor Groove Binders:&nbsp; Induced Fit 
Interactions of Heterocyclic Dications with the DNA Minor Groove&#x2020. Biochemistry 
2005, 44, 14701-14708. 
7. Ismail, M. A.; Arafa, R. K.; Brun, R.; Wenzler, T.; Miao, Y.; Wilson, W. D.; Generaux, 
C.; Bridges, A.; Hall, J. E.; Boykin, D. W. Synthesis, DNA Affinity, and Antiprotozoal Activity 
120 
 
 
of Linear Dications: Terphenyl Diamidines and Analogues. J. Med. Chem. 2006, 49, 5324-
5332. 
8. Ismail, M. A.; Brun, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Boykin, D. W. 
Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorganic & 
Medicinal Chemistry 2004, 12, 5405-5413. 
9. Wilson, W. D.; Nguyen, B.; Tanious, F. A.; Mathis, A.; Hall, J. E.; Stephens, C. E.; 
Boykin, D. W. Dications That Target the DNA Minor Groove: Compound Design and 
Preparation, DNA Interactions, Cellular Distribution and Biological Activity. Current 
Medicinal Chemistry - Anti-Cancer Agents 2005, 5, 389-408. 
10. Fitzgerald, D. J.; Anderson, J. N. Selective Nucleosome Disruption by Drugs That Bind 
in the Minor Groove of DNA. J. Biol. Chem. 1999, 274, 27128-27138. 
11. Baltz, T.; Baltz, D. G., C.; Crockett, J. Cultivation in a semi-defined medium of animal 
infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and 
T.gambiense. 
. EMBO Journal, 1985, 4, 1273-1277. 
12. Räz, B.; Iten, M.; Grether-Bühler, Y.; Kaminsky, R.; Brun, R. The Alamar Blue® assay 
to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in 
vitro. Acta Tropica 1997, 68, 139-147. 
13. Matile, H.; Pink, J. R. L. Plasmodium falciparum malaria parasite cultures and their 
use in immunology. In Immunological Methods. Academic Press San Diego, 1990; p 221−234. 
14. Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; 
Ruiz-Perez, L. M.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Deoxyuridine 
121 
 
 
Triphosphate Nucleotidohydrolase as a Potential Antiparasitic Drug Target. Journal of 
Medicinal Chemistry 2005, 48, 5942-5954. 
15. Takahashi, S.; Kuroyama, Y.; Sonogashira, K.; Hagihara, N. A Convenient Synthesis of 
Ethynylarenes and Diethynylarenes 
 Synthesis 1980, 627-630. 
16. Hay, A. Notes- Preparation of m- and p-Diethynylbenzenes. The Journal of Organic 
Chemistry 1960, 25, 637-638. 
17. Blackburn, B. K.; Lee, A.; Baier, M.; Kohl, B.; Olivero, A. G.; Matamoros, R.; Robarge, 
K. D.; McDowell, R. S. From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists 
Containing the 3,4-Dihydro-1H-1,4-benzodiazepine-2,5-dione Nucleus. Journal of Medicinal 
Chemistry 1997, 40, 717-729. 
122 
 
 
6. Synthesis of Arylimidamides as Potential Leishmanisis Treatment Agents 
Abstract 
The dicationic 2,5-diaryl furan furamidine and its derivatives have shown promising activities  
against a variety of protozoans with low toxicity. Our previous work with arylguanidines and 
arylimidamides analogs of 2,5-diaryl furan have shown exciting in vitro results. In this study, a 
series of new arylimidamides were synthesized by modification of 2,5-diaryl furan framework 
and were evaluated against  Leishmania amazonensis, Plasmodium falciparum, Trypanosoma 
brucei rhodesiense. DB 1852, DB 1853, DB 1890, and DB 1920 were found to be highly active 
against L.a. DB 1890 showed almost two fold higher activity whereas DB 1852 showed almost 
the same activity compared  to  a current medication, Amphotericin B. DB 1953 and DB 1920 
were found to be highly effective against Plasmodium falciparum and the tolerable cytotoxicity 
of these compounds make them promising for candidates for further development. 
6.1. Introduction 
The antimicrobial properties of diarylamidines in the treatment of protozoal diseases such as 
trypanosomiasis and leishmaniasis were discovered in the 1930s. In the 1970s, diarylamidine 
derivatives additional attention because of their activities against a number of pathogens, 
particularly Trypanosoma. 1 A large number of the diarylamidine derivatives were synthesized 
for evaluation. One diarylamidine analog, pentamidine, was found to be active against a variety 
of protozoa, including Trypanosoma brucei gambiense, Leismania donovani, and Pneumocystis 
carinii. Pentamidine became a widely used drug for infections caused by these micro-
organisms, especially in AIDS patients.2 A number of diarylamidine cationic derivatives have 
been shown to bind to the minor-groove of DNA at A-T sequences. This unique interaction of 
diarylamidines with the minor groove of DNA has been intensely investigated.3-5 While the 
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biological effects of these compounds are not fully understood, it is believed that initially the 
ligands bind to the minor groove and then inhibit DNA dependent enzymes such as 
topoisomerases, nucleases, etc.4, 6, 7  
HN
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O O
NH
NH2
HN
H2N
O NH
NH2
Pentamidine Furamidine, DB75
O
NHHN
NH HN
NN
DB 667
O
NHHN
NH HN
NN
DB 709
O O
O
NHHN
NH HN
NN
DB 710  
Figure 6.1. Structure of pentamidine, furamidine and previously synthesized arylimidamides.  
 
 The dicationic 2,5-diaryl furan furamidine was found to be an effective agent on intravenous 
administration, in rat model,  against P. carinii.8 Studies showed that DB 75 is more effective 
and less toxic than pentamidine upon intravenous administration. The N-alkyl derivatives of 
DB 75 gave similar results, however their toxicity was not as acceptable as DB 75.8 Moreover, 
additional evaluation with different parasitical species such as Giardia lamblia, Plasmodium 
falcifarum, and Trypanosoma rhodesience  DB 75 showed promising results as well.1, 9  
Recent work focused on the furamidine framework in which the amidine groups were replaced 
with guanidine groups. A series of 2,5-bis-(4-guanidinophenyl) furan analogs were evaluated 
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against microbial activity. These guanidino derivatives have shown promising in vitro activity 
against both C. albicans and M. tuberculosis.12 The conversion of guanidino phenyl moiety to 
arylimidamides gave compounds which showed both antifungal and antimycobacterial activity. 
Biophysical results also indicated that both the diguanidines and the arylimidamides in the 2,5-
diarylfuran system bind strongly to DNA. The arylimidamide analogs with terminal phenyl- 
and 2-prydyl- (DB 667) were found to be active against M. tuberculosis and antifungal species. 
In addition, the arylimidamide analogues DB 709, DB 710, and DB 667, were found to be more 
active than pentamidine against L.a. (0.37-0.53 µM).13 Therefore, arylimidamides have great 
potential for development for Leishmania infections. 
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Figure 6.2. The structure of synthesized arylimidamidines.  
 
Our previous work showed that modification of the phenyl units of DB 667 significantly 
affected the DNA binding affinity.12 To further these studies, a new series of arylimidamides 
was synthesized. The cyclopentyloxy and isobutoxy groups were substituted on the central 
phenyl rings. In addition, a small study investigated the variation of the terminal N-heterocyclic 
group.  
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6.2. Results and Discussion 
6.2.1. Synthesis 
The structure of arylimidamides can be viewed as composed of three different units; the central 
furan ring, modified phenyl groups on either side of the furan, and the terminal N-heterocycles. 
Our synthetic plan for the preparation of arylimidamides diamino compounds (22, 23) as the 
key precursor is shown in Figure 6.3. The diamino moieties can be achieved in two ways; 
reduction of the bis-nitrophenyl furans (20, 21) by catalytic hydrogenation or by the action of 
stannous chloride. The preparation of the bis-nitrophenyl furan analogs can be achieved starting 
with the appropriate substituted bromonitrobenzene and bis-alkylstannyl furan.14, 15   
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Figure 6.3. Retro synthetic approach for synthesizing arylimidamides.  
 
The synthesis began with the preparation of o-alkylbromonitrobenzene  analogs 14-16 in two 
steps, substitution of the aminogroup via a Sandmayer reaction followed by the alkylation of 
the phenolic hydroxyl group.16, 17  
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Scheme 6.1. The synthesis of o-alkylbromonitrobenzene derivatives. 
Reagents and conditions: i) NaNO2, NH2SO3H, CuBr, HBr, 58%; ii) KOtBu, THF/DMF, reflux 
14) iodocyclopentyl, 67%; 15) iodo-iso-butyl, 53%; 16) iodocyclohexyl, 10%.  
 
The commercially available 2-amino-5-nitro-phenol (12) was converted into 2-bromo-5-
nitrophenol (18) via Sandmayer reaction  in a 58% yield. 2-Bromo-5-nitrophenol 12 was 
alkylated with iodocyclopentyl, iodo-iso-butane, and iodocyclohexane under basic conditions 
to give compounds 14-16 in 67, 53, 10% yield, respectively. The cyclohexyl analogue was not 
investigated further due to the low yield obtained for synthesis of 16. 
O
17
OR3Sn SnR3
i
18; methyl
19; n-butyl
R
 
Scheme 6.2. Synthesis of 2,5 bis(trimethylstannyl)furan, 18 and 2,5 bis(tri-n-butylstannyl) 
furan,19. 
Reagents and conditions: 18; i) TMEDA, sec-BuLi, Me3SnCl, hexane, 0-10 oC, 27%.  
19; i) TMEDA, sec-BuLi, n-Bu3SnCl, hexane, 0-10 oC, 38%.  
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 To provide the cenral furan core, furan was reacted with sec-butyllithium to generate 2,5  
bis-lithiofuran, which was treated with trimethyltin chloride to yield compound 18, (27% 
yield). A similar procedure was repeated using tri-n-butyltin choloride to yield the compound 
19 (38% yield).  
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R1
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R1
14
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i
ii
 
Scheme 6.3. Synthesis of bis-aminophenyl furan derivatives, 22, 23.  
Reagents and conditions: 20; i) 14, 18, Pd(Ph3P), 1,4 dioxane, 80 oC., 74%. 21; i) 15, 19, 
Pd(Ph3P), 1,4 dioxane, 80 oC., 72%. ii) H2, Pd/C, EtAc, EtOH, (22, 68%; 23, 76%).   
 
The synthesis of 22 begins with a palladium (0) catalyzed  Stille coupling reaction with 2,5-
bis(trimethylstannyl) furan with compound 14 to yield  2,5-bis-(nitrophenyl)furan 20 (74% 
yield). Reduction of 20 was achieved by palladium-catalyzed hydrogenation to yield 22 (68% 
yield). A similar procedure was followed to prepare 23 by starting with 1-bromo-2-iso-butoxy-
4-nitrobenzene 15 with 2, 5-bis(tri-n-butyllstannyl) furan. Hydrogenation of 15 gave 23. 
n order to prepare the target arylimidamides the diamines 22 and 23 were arylated using the 
appropriate napthylmethylthioamides (38-44). The thioamides were prepared in two steps from 
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arylnitriles as show in Scheme 6.4.18-20 Two of the heterocyclic nitriles were not commercially 
available and were made in a two-step process from the appropriate heterocyclic aldehydes as 
shown in Scheme 6.5.  
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Scheme 6.4. Preparation of arylimidamides.  
Reagents and conditions: i) NaSH,  MgCl2.6H2O, DMF. ii) 2-bromo methylnaphthalene, 
CHCl3, reflux.   
 
IN-Methyl-2-pyrrolecarbonitrile 29 was synthesized from  N-Methyl-2-pyrrolealdehyde 45 in 
two steps by oxime formation followed by dehydration.21 A similar approach was used for 
synthesis of 1H-imidazole-4-carbonitrile 30, without isolation of oxime intermediate. Briefly,  
a solution of 1H-imidazole-4-carbaldehyde 47 in pyridine was treated with hydroxylamine 
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hydrochloride at room temperature followed by to addition of acetic anhydride to give the 
nitrile compound with a good yield, 72%.22 
It has been reported that arylimidamides exhibit antileishmanial and antimicrobial activity.12, 13 
In fact, some of the previously synthesized arylimidamide analogs have been found to be more 
active in vitro than current drugs used for Leishmaniasis treatment.   The activities of the newly 
synthesized arylimidamides (1-11) against L. amazonensis  (M), T. brucei rhodesiense 
(STIB900), P. falciparum (K1) in vitro, as well as their toxicities to L6 cell (rat myoblasts) are 
shown in Table 6.1.  
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45 46 29
47 30
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iii
 
Scheme 6.5. Synthesis of arylnitriles.  
Reagents and conditions: i) NH2OH.HCl, NaOAc, reflux, 77%. ii) Ac2O, reflux, 79%. iii) 
NH2OH.HCl, NaOAc, Ac2O, pyridine, 72%. 
 
6.2.2. Biology 
The activities of Mitefosine and Amphotericin B, which are two current medicines used to treat 
visceral leishmaniasis are included as controls in Table 6.1.As the table shows, these in vitro 
results are both promising and exciting as potential treatments for Leishmania.  Five of the  
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Table 6. 1. In vitro antiprozoan activity and cytotoxicity data for arylimidamides 1-11. 
O
NHHN
O
R1
O
R1
NH HN
R2 R21-11  
L.a. a  T.b.r. a  P.f. a   Cytotoxicityb  
IC50  IC50  IC50  IC50  
Compound R1 R2 
(µM) (µM) (µM) (µM) 
DB 1852,   1 pyridyl-    0.175 4.6 0.218 6.3 
DB 1853,   2 prymidyl-    0.208     0.215 0.024 5.0 
DB 1888,   3 cloropryl- >10 >113.1  76.2    >113.1 
DB 1889,   4 bromopyridyl- >10 >101.0 0.166    >101.0 
DB 1908,   5 1-H imidazyl- >10   3.21 0.292 7.5 
DB 1921,   6 
cy
cl
op
en
ty
l 
methyl-     4.680   4.12 0.378 2.2 
DB 1890,   7 pyridyl-    0.095   6.25 0.094 7.6 
DB 1920,   8 prymidyl-    0.493     0.192 0.022 6.0 
DB 1912,   9 cloropryl- >10  95.44    6.5      117.7 
DB 1913, 10 bromopyridyl- >10 >106.0  >5.0    >106.0 
DB 1909, 11 
is
ob
ut
hy
l 
1-H imidazyl- >10   4.08 0.163 6.9 
Miltefosine 15.0 ND ND ND 
AmB 
  
   0.16 ND ND ND 
 
a The L.a. (L. amazonensis), T.b.r.(Trypanosoma brucei rhodesiense) strain was STIB900, and the P. f. 
(Plasmodium falciparum) strain was K1. bCytotoxicity was evaluated using cultured L6 rat myoblast cells using 
the same assay procedure for T. b. r. 
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eleven arylimidamides were found to be more active than one of the current drugs (Miltefosine) 
against L. amazonensis  (M). DB 1852, DB 1853, DB 1890, DB 1920 were found to be highly 
active against L.a. DB 1852 activity is almost as good as the other current medication, 
Amphotericin B. DB 1890 showed almost two fold better activity than Amphotericin B. And, in 
addition to promising activity, the cytotoxicity of these compounds are tolerable. DB 1853 and 
DB 1920 were found to be highly active in vitro against Plasmodium falciparum. These two 
derivatives have terminal prymidyl groups. It appears that the structure of the terminal group 
plays an important role in P. f. activity. Over all, the prymidyl and pyridyl terminal units 
provide the best activity.  There is not a significant difference in in vito activity between the o-
cyclopentyl and o-isobutyl analogs. These studies show that the arylimidamide derivatives 
merit further evaluation for use against protozoan diseases. In vivo investigations against 
leishmania with DB 1852 and DB 1850 are underway.  
6.3. Conclusions 
A  small series of arylimidamides compounds were synthesized. Their activity  was evaluated 
in vitro against L. amazonensis, T. brucei rhodesiense, P. falciparum. DB 1852, DB 1853, DB 
1890, and DB 1920 were found to be highly active and had low cytotoxicities. These 
compounds are candidates for further evaluation against animal models of the diseases.    
6.4. Methods and Materials 
6.4.1. General Information 
All moisture and air sensitive reactions were carried out in glassware that was oven dried 
overnight and under dry nitrogen (passed through drying agents). Commercially supplied 
chemicals and reagents were used without additional purification. Ether and THF were distilled 
from Na and benzophenone. Triethylamine (CaH2) and ethanol (Mg/I2) were distilled from the 
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indicated drying agents. Ethanolic HCl solutions were prepared from fresh distilled dry ethanol 
that was treated with dry HCl gas for 10-15 min at ice bath temperature. Anhydrous DMF was 
purchased from Aldrich. TLC analysis was carried out on silica gel 60 F254 coated aluminum 
sheets and detection was  with two wavelengths of UV light. Column chromatography was 
performed with silica gel (flash 32-63 nm), from Dynamic Adsorbents Inc, in Norcross, GA. 
Melting points were recorded using a Mel-Temp 3.0 capillary melting point apparatus and are 
uncorrected. Mass spectrometry analyses were performed by the Mass Spectrometry Facilities 
of Georgia State University by chemical ionization under conditions which gave the protonated 
species M+1. Elemental analyses were performed by Atlantic Microlab, Atlanta, GA. 1H and 
13C NMR spectra were recorded a Bruker 400 MHz instrument. Chemical shifts (δ) are given in 
ppm relative to TMS (0 ppm), DMSO (2.49 ppm), CHCl3 (7.24 ppm) or MeOH (3.31 ppm) for 
1H spectra and TMS (0 ppm), DMSO (39.52 ppm), CHCl3 (77.16 ppm) or MeOH (49.00 ppm) 
for 13C spectra.  
6.4.2. In Vitro Assay  
In vitro efficacy and cyctotoxcity studies were performed at the Swiss Tropical Institute in 
Basel, Switzerland under the direction of Professor Reto Brun according to published 
procedures ( T.b.r,23 P.f.24, 25 and cyctotoxcity26). The in vitro L.a. data was provide by Karl 
Webovets at Ohio State University.  We are grateful for being provided these data by Professor 
Brun and Professor Werbovetz. 
6.4.3. Synthetic Prosedures 
2-Bromo-5-nitrophenol (13). 
Concentrated hydrobromic acid (200 mL) was added slowly to a mixture of 2-amino-5-
nitrophenol 12 (15 g, 97.4 mmol) and sulfamic acid (1.13g, 11.7 mmol) in water (300 mL) 
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while cooling in an ice cold-water bath. A solution of sodium nitrite (8.1 g, 116.8 mmol) in 
water (150 mL) was added dropwise while the reaction mixture was cooled with an ice-water 
mixture. After the addition of the sodium nitrite solution, the reaction mixture was stirred for an 
hour, and then CuBr (27.8 g, 194.8 mmol) in water (400 mL) was carefully added portionwise 
into the reaction mixture. The brown colored mixture was stirred for 4 h in a cold-water bath. 
The solid was collected by filtration. The residue was washed with water, dissolved in ethyl 
acetate (250 mL), and extracted three times with water (50 mL), and the organic layer was 
dried over MgSO4. After filtration and evaporation of the solvent, the crude product was 
purified by column chromatography on 50 g of silica gel and eluting with hexanes/ethyl acetate 
(20:1) to give  compound 18 as a pale yellow solid (11.2 g, 53%), mp: 120-121 oC;  (lit27 mp: 
119-120 oC).  1H NMR (CD3OD): δ 12.10 (s, 1H), 8.58 (d, J = 8.8 Hz, 1H), 8.52 (d, J = 2.4 Hz, 
1H), 8.38 (dd, J1= 2.4 Hz, J2= 9.0 Hz, 1H); 13C NMR (CD3OD): δ 164.5, 157.1, 143.1, 127.1, 
124.5, 119.7. 
1-Bromo-2-cyclopentyloxy-4-nitrobenzene (14). 
Potassium tert-butoxide (0.6 g, 5.5 mmol) was added to a solution of 2-bromo-5-nitrophenol 13 
(1 g, 4.6 mmol) in anhydrous THF (10 mL) and anhydrous DMF (2 mL) at 0 oC in an ice bath. 
The reaction mixture was stirred at 0 oC for 15 min. Then, iodocyclopentane (1.1 mL, 9.2 
mmol) was injected into the flask dropwise. The mixture was stirred for 30 min. at room 
temperature.  Then, a condensor was attached to the flask and the reaction mixture was allowed 
to reflux overnight. The solvent was removed under a vacuum. The red residue was dissolved 
in ethyl acetate (150 mL) and washed with 5% NaHCO3 (2 × 50 mL). The organic layer was 
dried over Na2SO4,  filtered  and solvent was removed under reduced pressure to yield a dark 
yellow solid. The crude material was purified by column chromatography with 30 g silica gel, 
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eluting with hexanes/ethyl acetate (20:1) to give a white solid (880 mg, 67%), mp: 46-47 oC. 1H 
NMR (CDCl3): δ 7.70-7.02 (m, 1H), 7.67-7.66 (m, 2H), 4.91 (q, J=2.4 Hz, 1H), 1.99-1.66 (m, 
8H); ); 13C NMR (CDCl3): δ 154.9, 147.8, 133.4, 120.7, 155.8, 108.3, 81.6, 32.6, 23.9. ESI-
MS: m/z calculated for C11H12BrNO3: 286.1; found: 286.1 (M). Analysis calculated for 
C11H12BrNO3: C, 46.17; H, 4.22; N, 4.89; found: C, 46.15; H, 4.25; N, 4.77 
1-Bromo-2-iso-butoxy-4-nitrobenzene (15). 
1-Bromo-2-isobutoxy-4-nitrobenzene 15 was synthesized by alkylation of 2-bromo-5-
nitrophenol 13 with 1-iodo-2-methylpropane by following a similar procedure to that used for 
the synthesis of 14, resulting in 15 as a pale yellow solid (53%), mp: 59-60 oC. 1H NMR 
(CDCl3): δ  7.64 (s, 3H), 3.85 (d, J=6.4 Hz, 2H),  2.18 (m, 1H), 1.08 (d, J = 6.8 Hz, 6H); 13C 
NMR (CDCl3): δ155.9, 147.9, 133.3, 119.9, 116.1, 107.1, 75.8, 28.2, 19.1; ESI-MS: m/z 
calculated for C10H12BrNO3: 273.0; found: 272.3 (M - H). Analysis calculated for 
C10H12BrNO3: C, 43.81; H, 4.41, N,5.10; found: C, 43.90; H, 4.35; N, 5.04.  
Alternative preparation of 1-bromo-2-iso-butoxy-4-nitrobenzene (15).  
NaH (60% in mineral oil) (330 mg, 5.5 mmol) was added portionwise into a solution of 13 (1g, 
4.5 mmol) in anhydrous DMF (10 mL) at 0 oC. The reaction mixture was stirred for 20 min. at 
0 oC, and 1-iodo-2-methylpropane (1.3 g, 6.8 mmol) was injected dropwise into the mixture 
with a syringe. The mixture was allowed to reflux for 24 h DMF was evaporated in vacuo and 
the resulting residue was dissolved in ethyl acetate (100 mL).  The solution was washed with 
NaOH 10% solution (3 × 30 mL), water (2 × 30 mL), and dried over Na2SO4. After filtration 
and evaporation of the solvent, the crude product was purified by column chromatography with 
15 g of silica gel, eluting with hexanes/ethyl acetate (20:1) to give a pale yellow solid (660 mg, 
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54%), mp: 60 oC. 1H NMR (CDCl3): δ  7.72 (s, 1H), 7.71 (d, J=0.8 Hz, 2H),  3.90 (d, J=6.4 
Hz, 2H),  2.22 (m, 1H), 1.12 (d, J = 6.8 Hz, 6H).  
1-Bromo-2-cyclohexyloxy-4-nitrobenzene (16). 
1-Bromo-2-cyclohexyloxy-4-nitrobenzene 16 was synthesized by alkylation of 2-bromo-5-
nitrophenol 13 with iodocyclohexane, following a similar procedure to that used for the 
synthesis of 14, to give 16 as a pale yellow solid (10%), mp: 31-32 oC. 1H NMR (CDCl3): δ  
7.74-7.73 (m, 1H), 7.71-7.70 (m, 2H), 4.50 (q, J = 3.2 Hz, 1H), 2.00-1.45 (m, 11H);   13C NMR 
(CDCl3): δ 154.8, 147.9, 133.7, 121.3, 116.2, 109.0, 77.2, 31,1, 25.4, 23.1; EI-MS: m/z 
calculated for C12H14BrNO3: 299.0; found: 299.0 (M). Analysis calculated for C12H14BrNO3: C, 
48.02 ; H, 4.70; N, 4.66; found: C,47.96; H, 4.70; N, 4.57.  
2,5-Bis(trimethylstannyl)furan (18).28  
A solution of 1.4 M sec-butyllithium (550 mL, 0.77 mol) in cyclohexane was added dropwise 
at 0 oC to a  mixture of furan (22.4 mL, 0.31 mol), TMEDA (116 mL, 0.77 mol) in fresh 
distilled hexanes (150 mL). After 2 hr stirring at 0 oC, the mixture was allowed to warm to 
room temperature. After stirring for 6 hr, the reaction mixture cooled to 0 oC and a solution of 
trimethyltin chloride (99g, 2.7 mol) in distilled hexanes (150 mL) was added dropwise. After 
addition, the reaction mixture was allowed to warm to room temperature. The reaction mixture 
was stirred for 36 h. A water solution of 1 N ammonium chloride (200 mL) was added at 0 oC 
dropwise. The organic layer was extracted with the ethyl acetate (200 mL). The organic layer 
was washed multiple times with an aqueous copper sulfate solution. The organic layer was 
dried over Na2SO4 and filtered. The solvent was removed under reduced pressure to give a 
yellow oil. Distillation of the crude product gave a pale yellow oil 13a (33 g, 27%), bp: 115-
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117 oC / 1.5 mmHg,  lit28 bp 90-91 oC / 0.5 torr. 1H NMR (CDCl3): δ  6.61 (d, J= 4.0 Hz, 2H), 
0.31 (s, 18 H);   13C NMR (CDCl3): δ 165.2, 120.5, -0.45.  
2,5-Bis(tri-n-butylstannyl)furan (19). 
2,5-Bis(tri-n-butylstannyl)furan 19 was synthesized by following a similar procedure to that 
used for the synthesis of 18 by using tri-n-butyltin chloride, to give 19 as a pale yellow oil 
(38%), bp: 175-177 oC/ 0.015 mmHg, lit29 bp: 222-224 oC / 0.6 mmHg. 1H NMR (CDCl3): δ  
6.58 (d, J= 2.0 Hz, 2H), 1.66-1.05 (m, 54H); 13C NMR (CDCl3): δ 164.3, 120.4, 29.1, 27.3, 
18.3, 16.4.   
2,5-Bis-(2-cyclopentyloxy-4-nitrophenyl)furan (20). 
2,5-Bis(trimethylstannyl)furan 18 (606 mg, 1.5 mmol) was injected into a solution of 1-bromo-
2-cyclopentyloxy-4-nitrobenzene 14 (880 mg, 3.1 mmol) and tetrakis-
(triphenylphosphine)palladium(0) (54 mg, 0.04 mmol) in anhydrous 1,4-dioxane (10 mL) at 
room temperature under nitrogen. The mixture was allowed to reflux under nitrogen overnight. 
The orange colored suspension was diluted with hexanes (8mL) and cooled to room 
temperature. The residue was filtered and washed with hexanes. The orange fluffy residue was 
recrystallized from toluene (25 mL) to give  yellow fluffy solid (1.1 g, 74%), mp : 271-273 oC. 
1H NMR (CDCl3): δ  8.08 (d, J=8.8 Hz, 2H), 7.91 (dd, J1=2.0 Hz, J2= 9.0 Hz, 2H), 7.27 (d, J= 
2.0 Hz, 2H), 7.29 (s, 2H), 5.08-5.04 (m, 2H), 2.12-1.74 (m, 16H) ;   13C NMR (CDCl3): δ 
153.9, 148.9, 147.0, 125.9, 125.5. 116.1, 115.8, 107.9, 80.9, 32.9, 24.1; ESI-MS: m/z calculated 
for C26H26N2O7: 478.1; found: 479.0 (M+1). Analysis calculated for C12H14BrNO3: C, 65.20; 
H,5.47; N, 5.85; found: C, 64.90; H, 5,76; N, 5.85.  
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2,5-Bis(2-iso-butoxy-4-nitrophenyl)furan (21). 
2,5-Bis(2-isobutoxy-4-nitrophenyl)furan 21 was synthesized by following a similar procedure 
to that used for the synthesis of 20 using 2,5-bis-tri-n-butylstannanyl furan 19, to give 21 as a 
yellow fluffy solid (72%), mp: 230-232 oC. 1H NMR (CDCl3): δ 8.10 (d, J= 8.8 Hz, 2H), 7.94 
(d, J=8.4 Hz, 2H), 7.82 (s, 2H), 7.36 (s, 2H), 4.01 (d, J=6 Hz, 4H), 2.35-2.28 (m, 2H), 1.16 (d, 
J= 6.8 Hz, 12H);   13C NMR (CDCl3): δ155.1, 148.9, 147.1, 125.9, 124,9, 116.2, 116.1, 106.9, 
75.8, 28.3, 19.5.  ESI-MS: m/z calculated for: C24H26N2O7: 454.1; found: 455.2 (M+1). 
Analysis was calculated for C24H26N2O7-0.7H2O: C, 61.71; H, 5.91; N, 5.99; found: C, 61.61; 
H,5.65 ; N, 5.59. 
2,5-Bis-(2-cyclopentyloxy-4-aminophenyl)furan (22). 
To a suspension of 2,5-bis(2-cyclopentyloxy-4-nitrophenyl)furan 20 (2.5 g, 5.21 mmol) in a 
mixture of ethyl acetate (50 mL) and anhydrous ethanol (20 mL), Pd/C (500 mg, 10%) was 
added. The suspension was bubbled with dry nitrogen for 15 min. and hydrogenated overnight 
using a Parr apparatus with a starting pressure of  50 psi.  The consumption of hydrogen gave a 
clear solution. The solution was filtrated over well-packed celite, and the filtrate was removed 
under reduced pressure to give a light brown fluffy solid (1.4 g, 64%), mp : 114-116 oC. 1H 
NMR (d6-DMSO): δ  7.51 (d, J= 8.0 Hz, 2H), 6.60 (br s, 2H), 6.35 (s, 2H), 6.30 (d, J= 1.6 Hz, 
2H), 6.23 (d, J= 6.8 Hz, 2H ), 5.40 (br s, 3H), 4.82-4.79 (m, 2H), 3.57 (s, 2H), 1.97-1.61 (m, 
16H), 1.69-1.63 (m, 16 H);   13C NMR (d6-DMSO): δ;154.3, 148.8, 148.0, 125.9, 108.6, 107.7, 
106.2, 99.0, 78.6, 32.5, 23.7. ESI-MS: m/z calculated for  C26H30N2O3: 418.2; found: 419.1 
(M+1). Analysis calculated for C26H30N2O3: C, 74.61; H, 7.22; N, 6.69; found: C, 74.55; H, 
7.19; N, 6.99. 
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2,5-Bis-(2-iso-butyloxy-4-aminophenyl)furan (23). 
2,5-Bis(2-isobutoxy-4-aminophenyl)furan 23 was synthesized by following a similar procedure 
to that used for the synthesis of 22, to give a fluffy light orange-solid (76 %), mp: 91-92 oC. 1H 
NMR (CDCl3): δ 7.78 (d, J= 8.0 Hz, 2H), 6.88 (s, 2H), 6.38 (d, J= 8.0 Hz, 2H), 6.29 (s, 2H), 
3.82 (d, J=6 Hz, 4H), 3.71( br s, 2H), 2.26-2.24 (m, 2H),  1.14 (d, J= 6.8 Hz, 12H);   13C NMR 
(CDCl3): δ 156.1, 148.3, 146.3, 126.8, 111.7, 109.4, 107.2, 99.1, 74.7, 28.4, 19,6. ESI-MS: m/z 
calculated for C24H30N2O3: 394.2; found: 395.2 (M+1). Analysis calculated for C24H30N2O3: C, 
73.07; H, 7.66; N, 7.10; found: C, 73.29; H, 7.92; N, 7.07.  
1-Methyl-1H-pyrrole-2-carbaldehyde oxime (46).21 
1-Methyl-2-pyrrolecarboxaldehyde 45 (25 g, 0.23 mol) was added portionwise in a solution of 
hydroxylamine hydrochloride (24 g, 0.34 mol) and sodium acetate ( 28 g, 0.34 mol) at 0 oC. 
The reaction mixture was allowed to warm to room temperature and stirred overnight. The 
reaction mixture was poured into (500 mL) water and filtered. The residue was washed with 
water and crystallized from ethanol to give a pale pink solid (22 g, 77%), mp: 154-156  oC;  
(lit30 mp: 148.5-149.5 oC). 1H NMR (CDCl3): δ 8.90 (br s, 1H), 7.44 (s, 1H), 7.33 (dd, J1= 1.6 
Hz, J2= 4.0 Hz, 1H), 6.72 (t, J=2.4 Hz, 1H), 6.26-6.24 (m, 1H), 3.76 (s, 3H);   13C NMR 
(CDCl3): δ 136.1, 125.5, 123.1, 118.5, 108.8, 34.4.  
1-Methyl-1H-pyrrole-2-carbonitrile (29).21 
1-Methyl-1H-pyrrole-2-carbaldehyde oxime 46 (20 g, 0.16 mol) was heated at refluxed in an 
acetic anhydride (150 mL) for 3 hr and was extracted with dichloromethane (3×300 mL) and  
dried over MgSO4. After filtration, the organic layer was removed under reduced pressure to 
give a yellow oil. The crude product was purified by column chromatography with 50 g of 
silica gel, eluting with hexanes/ethyl acetate (50:1) to give the compound 29 as a pale yellow 
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oil (13.5 g, 79%),  (lit30 bp: 89-90 oC/ 1.5 mmHg). 1H NMR (CDCl3): δ 6.80 (t, J= 2.0 Hz, 1H), 
6.72 (dd, J1= 1.6 Hz, J2= 4.0 Hz, 1H), 6.13-6.11 (m, 1H), 3.72 (s, 3H);   13C NMR (CDCl3): δ 
127.7, 119.7, 113.8, 109.3, 104.2, 35.2.  
1H-imidazole-4-carbonitrile (30).22 
Hydroxylamine hydrochloride (5.4 g, 78 mmol) was added to a solution of 1H-imidazole-4-
carbaldehyde 47 (5 g, 52 mmol) in pyridine (15 mL). After stirring for 2 h at room temperature, 
the reaction mixture was heated at 80 oC and acetic anhydride (40mL) was added dropwise 
over 2 h. Then, the mixture was allowed to cool to room temperature and was stirred overnight. 
The pH of the reaction mixture was adjusted to 8.0 with 10% NaOH solution and extracted 
with ethyl acetate (3 ×300 mL). The organic layers were combined, washed three times with 
brine and dried over K2CO3. After filtration, the organic solvent was removed under reduced 
pressure to give a white solid. The crude material was further washed with ether to give 30 as a 
white solid (3.5 g, 72%), mp: 141.0-143.0  (lit31 mp: 143.5-144.5). 1H NMR (d6-DMSO): δ 
13.00 (br s, 1H), 8.08 (s, 1H), 7.89 (s, 1H);   13C NMR (d6-DMSO): δ 138.5, 127.3, 116.4, 
112.2.  
Pyrimidine-2-carbothioamide (31).  
Pyrimidine-2-carbonitrile (500 mg, 4.76 mmol) was added to a mixture of slurry of sodium 
hydrosulfide hydrate (704 mg, 9.52 mmol) and magnesium chloride hexahydrate in DMF (15 
mL) at room temperature. The resulting green slurry mixture was stirred overnight at room 
temperature. The mixture was poured into water (200 mL). The yellow precipitate was 
collected by filtration and washed with water. The crude product was dissolved in DCM (250 
mL) and dried on K2CO3. The organic layer was filtered through celite, concentrated under 
reduced pressure The yellow crude product was crystallized with DCM and gave a yellow solid 
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(550 mg, 83%), mp: 203-204 oC. 1H NMR (MeOD): δ  8.89 (d, J= 4.8 Hz, 2H), 7.59 (t, J= 4.8 
Hz, 1H);   13C NMR (CDCl3): δ 194.8, 158.5, 157.2, 122.2. ESI-MS: m/z calculated for 
C5H5N3S: 139.0; found: 140 (M+1). Analysis calculated for C5H5N3S: C, 43.14; H, 3.62; N, 
30.19; found: C, 43.37; H, 3.64; N, 29.98. 
Pyridine-2-carbothioamide  (32).  
32 was synthesized by following a similar procedure to that used for the synthesis of 31, 
starting with pyridine-2-carbonitrile  to yield   a yellow solid (86%), mp: 138-140 oC, (lit12 mp: 
136-137 oC).  1H NMR (d6-DMSO): δ 9.93-9.74 (br d, 2H, NH), 8.58-8.49 (m, 2H), 7.95 (t, J= 
7.6 Hz, 1H), 7.57 (t, J= 6.8 Hz, 1H); 13C NMR (d6-DMSO): δ 194.7, 151.6, 147.2, 136.9, 
125.9, 124.1. ESI-MS: m/z calculated for C6H6N2S: 138.0; found: 139.0 (M+1).  
5-Chloropyridine-2-carbothioamide (33). 
33 was synthesized by following a similar procedure to that used for the synthesis of 31, 
starting with 5-chloropyridine-2-carbonitrile  to give yellow solid (67%), mp: 130-131 oC. 1H 
NMR (CDCl3): δ 9.34 (br s, 1H, NH), 8.67 (d, J= 8.8 Hz, 1H), 7.78 (br s, 1H, NH), 7.81 (dd, 
J1= 2.4 Hz, J2= 9.0 Hz, 1H); 13C NMR (CDCl3): δ 194.5, 148.6, 146.1, 136.7, 135.5, 126.3. 
ESI-MS: m/z calculated for C6H5ClN2S: 171.9; found: 173.0 (M+1). Analysis calculated for 
C6H5ClN2S: C, 41.74; H, 2.92; N, 16.22; found: C, 41.67; H, 2.90; N, 15.99. 
5-Bromopyridine-2-carbothioamide (34). 
34  was synthesized by following a similar procedure to that used for the synthesis of 31, 
starting with 5-bromopyridine-2-carbonitrile  to give a yellow solid (73%), mp: 138-139 oC. 1H 
NMR (CDCl3): δ 9.33 (br s, 1H, NH), 8.64-8.56 (m, 2H), 7.97 (dd, J1= 2.4 Hz, J2= 8.0 Hz, 
1H), 7.79 (br s;1H); 13C NMR (CDCl3): δ 194.7, 148.9, 148.3, 139.6, 126.6, 124.7. ESI-MS: 
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m/z calculated for C6H5BrN2S: 217.1; found: 217.0 (M). Analysis calculated for C6H5BrN2S: C, 
33.19; H, 2.32; N, 12.90; found: C, 33.60; H, 2.32; N, 13.09. 
1H-Imidazole-4-carbothioamide (35). 
 35 was synthesized by following a similar procedure to that used for the synthesis of 31, 
starting with 1H-imidazole-4-carbonitrile 30 and yielded a yellow solid (71%), mp: 209-211 
oC. 1H NMR (d6-DMSO): δ 9.33-9.03 (br d, 2H, NH), 7.78 (s, 1H), 7.75 (s, 1H), 2.40 (br s, 1H, 
NH); 13C NMR (d6-DMSO): δ 194.8, 145.4, 141.2, 128.4. ESI-MS: m/z calculated for 
C6H8N2S: 127.1; found: 128.1 (M+1). Analysis calculated for C4H5N3S: C, 37.77; H, 3.96; N, 
33.04; found: C, 37.84; H, 3.98; N, 32.95. 
1-Methyl-1H-pyrrole-2-carbothioamide (36). 
 36 was synthesized by following a similar procedure to that used for the synthesis of 31, 
starting with 1-methyl-1H-pyrrole-2-carbonitrile 29 to yield a yellow solid (75%), mp: 87-88 
oC. 1H NMR (d6-DMSO): δ 9.93-9.74 (br d, 2H, NH), 6.99 (s, 1H), 6.68 (q, J= 2.0 Hz, 1H), 
6.02 (t, J= 2.8 Hz, 1H), 3.95 (s, 3H) ; 13C NMR (d6-DMSO): δ 189.4, 132.6, 130.6, 112.6, 
106.9, 37.5. ESI-MS: m/z calculated for C6H8N2S: 140.0; found: 141.0 (M+1). Analysis 
calculated for C5H5N3S: C, 51.39; H, 5.75; N, 19.98; found: C, 51.27; H, 5.92; N, 20.06. 
S-(2-naphthylmethyl)-2-pyridylthioimidate hydrobromide (38).12 
2-Bromomethylnaphthalene (19 g, 86.9 mol) was added to a solution of pyrimidine-2-
carbothioamide 32 (10 g, 72.4 mol) in dry chloroform (350 mL). The reaction mixture was 
heated at reflux for 36 h. The reaction mixture was allowed to cool to room temperature and the 
white participate was filtered. The white fluffy solid was washed with dry ether and dry 
dichloromethane,  dried under reduced pressure  to yield a white fluffy solid (15.3 g, 59%), mp: 
187-188 oC, (lit12  mp: 192 oC).  1H NMR (d6-DMSO): δ 11.20 (s, 1H, NH), 8.92 (d, J= 5.4 Hz, 
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2H), 8.25 (d, J=8.0 Hz, 1H), 7.89 (s, 1H), 7.83-7.81 (m, 3H), 7.63-7.59 (m, 1H), 7.54 (d, J=8.4 
Hz, 1H), 7.45-7.43 (m, 2H), 4.48 (s, 2H).  
S-(2-naphthylmethyl)-2-pyrimidylthioimidate  hydrobromide (39). 
39 was synthesized by following a similar procedure to that used for the synthesis of 38, 
starting with 31 to give a white fluffy solid (53%), mp: 175-176 oC. 1H NMR (d6-DMSO): δ 
11.30 (br s, 1H, NH), 8.97 (d, J= 5.4 Hz, 2H), 7.95 (s, 1H), 7.89-7.85 (m, 3H), 7.66 (t, J=5.2 
Hz, 1H), 7.57 (dd, J1=1.6, J2=8.0 Hz, 1H), 7.45-7.43 (m, 2H), 4.48 (s, 2H). ESI-MS: m/z 
calculated for C16H13N3S: 279.3; found: 280.2 (M+1). Analysis calculated for C16H13N3S-
2HBr-0.2H2O: C, 43.03; H, 3.52; N, 9.40; found: C, 43.20; H, 3.78; N, 9.17. 
S-(2-Naphthylmethyl)-5-chloro-2-pyridylthioimidate hydrobromide (40). 
40 was synthesized by following a similar procedure to that used for the synthesis of 38, 
starting with 32 and resulted in a white fluffy solid (58%), mp: 201-202 oC. 1H NMR (MeOD): 
δ 8.84 (t, J=1.2 Hz, 1H), 8.20 (d,  J=1.6 Hz, 2H), 7.82-7.76 (m, 4H), 7.50-7.42 (m, 3H), 3.90 
(s, 2H). ESI-MS: m/z calculated for C17H13ClN2S: 312.0; found: 313.1 (M+1). Analysis 
calculated for C17H14BrClN2S: C, 51.86; H, 3.58; N, 7.11; found: C, 51.59; H, 3.53; N, 7.00. 
S-(2-Naphthylmethyl)-5-bromo-2-pyridylthioimidate hyrobromide (41). 
41 was synthesized following a similar procedure to that used for the synthesis of 38, starting 
with 33 and resulted in a white fluffy solid (66 %), mp: 204-205 oC. 1H NMR (MeOD): δ 8.96 
(s, 1H), 8.36 (dd,  J1= 2.0 Hz, J2= 8.0 Hz 1H), 8.13 (d, J= 8.4 Hz, 1H),  7.83-7.77 (m, 4H), 
7.51-7.45 (m, 3H), 3.91 (s, 2H). ESI-MS: m/z calculated for C17H13BrN2S: 357.0; found: 357.3 
(M+1). Analysis calculated for C17H14Br2N2S-0.4H2O: C, 45.84; H, 3.34; N, 6.28; found: C, 
45.85; H, 3.13; N, 6.69.  
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S-(2-Naphthylmethyl)-4-1H-imidazylthioimidate hyrobromide (42). 
42 was synthesized by following a similar procedure to that used for the synthesis of 38, 
starting with 36 and resulted in a white fluffy solid (53%), mp: 175-176 oC. 1H NMR (d6-
DMSO): δ 11.30 (br s, 1H, NH), 8.97 (d, J= 5.4 Hz, 2H), 7.95 (s, 1H), 7.89-7.85 (m, 3H), 7.66 
(t, J=5.2 Hz, 1H), 7.57 (dd, J1=1.6, J2=8.0 Hz, 1H), 7.45-7.43 (m, 2H), 4.48 (s, 2H). ESI-MS: 
m/z calculated for C16H13N3S: 280.3; found: 280.2 (M). Analysis calculated for C16H13N3S-
2HBr-0.2H2O: C, 43.03; H, 3.52; N, 9.40; found: C, 43.20; H, 3.78; N, 9.17. 
S-(2-Naphthylmethyl)-4-1-methyl-1H-pyrrolethioimidate hyrobromide (43). 
43 was synthesized by following a similar procedure to that used for the synthesis of 38, 
starting with 35 and resulted in a white fluffy solid (64%), mp: 187-190 oC. 1H NMR (MeOD): 
δ 8.33 (s, 1H), 8.02 (s, 1H), 7.98 (s, 1H), 7.94-7.88 (m, 3H), 7.59-7.52 (m, 3H), 4.84 (s, 2H). 
ESI-MS: m/z calculated for C15H13N3S: 267.3; found: 268.1 (M+1).  Analysis calculated for 
C15H13N3S-HBr: C, 51.73; H, 4.05; N, 12.06; found: C, 51.04; H, 3.83; N, 12.76 
2,5-Bis[2-cyclopentoxyl-4-(2-pyridylimino)aminophenyl]furan.HCl (1). 
38 (371 mg, 1.03 mmol) was added into a cooled solution of 2,5-bis-(2-cyclopentyloxy-4-
aminophenyl)furan 22 (200 mg, 0.47 mmol) in mixture of  dry ethanol (10 mL) and dry 
acetonitrile (5 mL) in an ice bath. The reaction mixture was  stirred at room temperature 
overnight. After the disappearance of the starting material, the organic solvent was removed 
under reduced pressure to yield a crude oil product. Dry ether (20 mL) was added to the crude 
material and the mixture was stirred at room temperature for 4 h. The red participate was 
filtered and washed with dry ether. The solid was dissolved in water, the solution was cooled to 
0 oC in a ice bath and 10% NaOH was added until pH reached approximately 10. The free base 
was participated, and then extracted into dichloromethane (2 ×200 mL). The organic layer was 
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washed with distilled water, dried over K2CO3, filtered and removed under reduced pressure. 
The resulting yellow solid was crystallized from dichloromethane/hexane mixture and filtrated. 
The free base yellow solid was characterized with NMR. Then the free base was suspended in 
dry ethanol (10 mL) and cooled to  0 oC in a ice bath. Freshly prepared hydrochloric ethanol (2 
mL) was added into the suspension and the mixture was stirred at room temperature overnight. 
The resulting red solution was concentrated under vacuo.  The red crude solid was crystallized 
with dry ethanol and dry ether and filtered to yield an red-orange solid (120 mg, 36%), mp: 
208-210 oC. 1H NMR (d6-DMSO): δ 11.90 (br s, 2H, NH), 10.08 (s, 2H, NH), 9.32 (s, 2H, NH), 
8.90 (s, 2H), 8.42 (s, 2H), 8.23-8.13 (m, 4H), 7.86 (s, 2H), 7.28-7.13 (m, 6H), 5.05 (s, 2H), 
2.01-1.68 (m, 16H) ;   13C NMR (d6-DMSO): δ 159.9, 154.6, 150.3, 148.5, 144.9, 138.8, 134.6, 
129.0, 127.0, 124.4, 119.4, 118.1, 113.3, 111.5, 80.4, 32.7, 24.1; ESI-MS: m/z calculated for 
C38H38N6O3: 626.3; found: 627.2 (M+1). Analysis calculated for C38H38N6O3-3.5HCl-
0.6C4H10O: C, 60.74; H, 5.99; N, 10.52; found: C, 60.75; H, 6.02; N, 10.47. 
2,5-Bis[2-cyclopentoxyl-4-(2-pyrimidylimino)aminophenyl]furan.HCl (2). 
2 was synthesized by following a similar procedure to that used for the synthesis of 1, starting 
with 39 and resulted in a dark red solid (48%), mp: 210-212 oC. 1H NMR (d6-DMSO): δ 12.00 
(br s, 2H, NH), 10.15 (s, 2H, NH), 9.66 (s, 2H, NH), 9.21 (d, J=4.8 Hz, 4H), 8.12 (d, J=8.4 Hz, 
2H), 7.97 (t, J=4.8 Hz, 2H), 7.27 (s, 2H), 7.15-7.12 (m, 4H), 5.03 (s, 2H), 2.07-1.68 (m, 16H) ;   
13C NMR (d6-DMSO): δ 158.8, 157.4, 154.5, 148.5, 134.9, 126.9, 125.4, 119.5, 118.1, 113.4, 
111.6, 80.3, 32.7, 24.1; ESI-MS: m/z calculated for C36H36N8O3:700.2; found: 701.1 (M+1). 
Analysis calculated for C36H36N8O3-4HCl-0.3C4H10O: C, 56.07; H, 5.44; N, 14.06; found: C, 
56.06; H, 5.72; N, 14.10. 
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2,5-Bis[2-cyclopentoxyl-4-(5-chloro-2-pyridylimino)aminophenyl]-furan.HCl (3). 
3 was synthesized by following a similar procedure to thats used for the synthesis of 1, starting 
with 40 and resulted in a bright red solid (52%), mp: 247-249 oC. 1H NMR (MeOD): δ 8.92 (d, 
J=1.6 Hz, 2H), 8.33-8.19 (m, 6H), 7.24-7.18 (m, 6H), 5.11 (s, 2H), 2.09-1.78 (m, 16H) ;   13C 
NMR (MeOD): δ 159.8, 154.9, 149.0, 148.5, 142.5, 137.8, 137.1, 133.1, 126.8, 124.0, 120.7, 
116.9, 113.1, 110.4, 80.4, 32.4, 23.6; ESI-MS: m/z calculated for C38H36Cl2N6O3: 795.3; found: 
695.3 (M). Analysis calculated for C38H36Cl2N6O3-2HCl-1.5H2O: C, 57.36; H, 5.19; N, 10.56; 
found: C, 57.55; H, 5.19; N, 10.18. 
2,5-Bis[2-cyclopentoxyl-4-(5-bromo-2-pyridylimino)aminophenyl]furan.HCl (4). 
4 was synthesized by following a similar procedure to that used for the synthesis of 1, starting 
with 41 and resulted in a bright red solid (57%), mp: 256-257 oC. 1H NMR (MeOD): δ 9.02 (d, 
J=1.6 Hz, 2H), 8.44 (dd, J1=2.0, J2=8.0 Hz, 2H), 7.25-7.19 (m, 4H), 7.24-7.18 (m, 6H),  5.10 
(s, 2H), 2.07-1.78 (m, 16H) ;   13C NMR (MeOD): δ 159.8, 154.9, 151.3, 148.4, 142.9, 140.8, 
133.1, 126.7, 124.2, 120.7, 116.9, 113.1, 110.4, 80.4, 32.4, 23.6; ESI-MS: m/z calculated for 
C38H36Br2N6O3: 782.1; found: 783.3 (M+1). Analysis calculated for C38H36Br2N6O3-2HCl -
1.8H2O: C, 51.23; H, 4.71; N, 9.43; found: C, 50.90; H, 4.69; N, 9.26. 
2,5-Bis[2-cyclopentoxyl-4-(4-1H-imidylimino)aminophenyl]-furan.HCl (5). 
5 was synthesized by following a similar procedure to that used for the synthesis of 1, starting 
with 42 and  resulted in an orange solid (55%), mp: 255-258 oC. 1H NMR (MeOD): δ 8.26 (s, 
2H), 8.19 (s, 2H), 8.14 (d, 8.4 Hz, 2H), 7.16-7.11 (m, 6H),  5.07 (d, J=2.8 Hz, 2H), 2.05-1.74 
(m, 16H);   13C NMR (MeOD): δ 157.4, 156.3, 149.9, 139.3, 134.5, 128.9, 128.1, 124.3, 121.8, 
118.2, 114.4, 111.7, 81.8, 33.9, 25.1; ESI-MS: m/z calculated for C32H36N8O3 -2HCl: 604.2; 
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found: 605.3 (M-2HCl). Analysis calculated for C34H36N8O3-4HCl-5H2O: C, 48.57; H, 5.99; N, 
13.33; found: C, 48.61; H, 5.34; N, 13.02. 
2,5-Bis[2-cyclopentoxyl-4-(methyl)aminophenyl]-furan.HCl (6). 
6 was synthesized by following a similar procedure to that used for the synthesis of 1, starting 
with S-(2-naphthylmethyl)methylthioimidate.HBr salt 44 which was previously prepared in our 
lab, resulted in an orange solid (57%), mp: 225-228 oC. 1H NMR (MeOD): δ 8.11 (d, 8.4 Hz, 
2H), 7.14 (s, 2H), 7.06-7.02 (m, 4H), 5.08-5.05 (m, 2H), 2.46 (s, 6H), 2.05-1.74 (m, 16H);   13C 
NMR (MeOD): δ 165.2, 154.8, 148.3, 133.1, 126.7, 120,4, 116.5, 112.8, 110.0, 80.3, 32,4, 
23.6, 17.7; ESI-MS: m/z calculated for C30H36N4O3: 500.2; found: 501.2 (M+1). Analysis 
calculated for C30H36N4O3-2HCl-0.4CH2Cl2-0.7C4H10O: C, 60.47; H, 7.00; N, 8.49; found: C, 
60.79; H, 6.61; N, 8.24. 
2,5-Bis[2-isobutoxyl-4-(2-pyridylimino)aminophenyl]-furan.HCl (7). 
7 was synthesized by following a similar procedure to that used for the synthesis of 1, starting 
with 38 and 2,5-bis(2-isobutyloxy-4-aminophenyl)furan 23 and resulted in a orange-red solid 
(60%), mp: 201-203 oC. 1H NMR (MeOD): δ 8.92 (d, J=4.8 Hz, 2H), 8.32 (d, J=8.0 Hz, 2H), 
8.23-8.18 (m, 4H), 7.85-7.83 (m, 2H), 7.27-7.21 (m, 6H), 4.04 (d, J=6.4 Hz, 4H)   2.32-2.30 
(m, 2H), 1.19 (d, J=6.8 Hz, 12H);   13C NMR (MeOD): δ160.3, 156.1, 150.0, 148.4, 144.1, 
138.2, 133.4, 128.4, 126.7, 122.9, 120.1, 117.2, 113.1, 109.3, 75.2, 28.1, 18.4; ESI-MS: m/z 
calculated for C36H38N6O3-2HCl: 602.3; found: 603.4 (M+1). Analysis calculated for 
C36H38N6O3-2HCl -2.85H2O: C, 59.47; H, 6.33; N, 11.56; found: C, 59.45; H, 6.36; N, 11.19 
2,5-Bis[2- iso-butoxyl -4-(2-pyrimidylimino)aminophenyl]furan.HCl (8). 
8 was synthesized by following a similar procedure to that used for the synthesis of 7, starting 
with 39 and resulted in a red solid (55%), mp: 200-201 oC. 1H NMR (MeOD): δ 9.17 (d, J=4.8 
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Hz, 4H), 8.23 (d, J=8.4 Hz, 2H), 7.89 (t, J=5.2 Hz, 2H), 7.29-7.23 (m, 6H), 4.05 (d, J=6.0 Hz, 
4H)   2.36-2.29 (m, 2H), 1.19 (d, J=6.4 Hz, 12H);   13C NMR (MeOD): δ171.6, 158.1, 157.4, 
156.1, 152.8, 148.4, 133.2, 126.6, 124.6, 120.1, 117.2, 113.2, 109.3, 75.2, 28.1, 18.4; ESI-MS: 
m/z calculated for C34H36N8O3: 604.3; found: 605.3 (M+1). Analysis calculated for 
C34H36N8O3-2HCl -0.8CH2Cl2-0.8C4H10O: C, 56.07; H, 6.01; N, 13.76; found: C, 56.07; H, 
5.69; N, 13.86 
2,5-Bis[2- iso-butoxyl -4-(5-choloro-2-pyridylimino)aminophenyl]furan.HCl (9). 
 9 was synthesized by following a similar procedure to that used for the synthesis of 7, starting 
with 40 and resulted in a bright red solid (61%), mp: 275 oC. 1H NMR (MeOD): δ 8.92 (d, 
J=0.8 Hz, 2H), 8.32-8.20 (m, 6H), 7.27-7.20 (m, 6H), 4.04 (d, J=6.4 Hz, 4H), 2.33-2.29 (m, 
2H), 1.18 (d, J=6.8 Hz, 6H)  ;   13C NMR (MeOD): δ 161.0, 157.6, 150.5,149.9, 144.0, 139.3, 
138.6, 134.7, 128.1, 125.4, 121.6, 118.6, 114.6, 110.7, 76.7, 29.6, 19.8; ESI-MS: m/z calculated 
for C36H36Cl2N6O3: 670.2; found: 671.3 (M+1). Analysis calculated for C36H36Cl2N6O3-2HCl-
1.1H2O: C, 56.56; H, 5.30; N, 10.99; found: C, 56.36; H, 5.27; N, 10.83. 
2,5-Bis[2-iso-butoxyl-4-(5-bromo-2-pyridylimino)aminophenyl]furan.HCl (10). 
10 was synthesized by following a similar procedure to that used for the synthesis of 7, starting 
with 41 and resulted in a red solid (52%), mp: 2-271-272 oC. 1H NMR (MeOD): δ 9.00 (d, 
J=2.0 Hz, 2H), 8.40 (dd, J1=2.4, J2=8.0 Hz, 2H), 8.20 (t, J=9.6, 4H), 7.24-7.18 (m, 6H),  4.02 
(d, J=6.4 Hz, 4H), 2.31-2.28 (m, 2H), 1.16 (d, J=6.8 Hz, 6H);   13C NMR (MeOD): δ 159.8, 
156.2, 151.3, 148.4, 142.9, 140.8, 133.3, 126.7, 126.1, 124.2, 120.1, 117.2, 113.2, 109.3, 75.2, 
28.1, 18.4; ESI-MS: m/z calculated for C36H36Br2N6O3: 758.1; found: 759.3 (M+1). Analysis 
calculated for C36H36Br2N6O3-2HCl -0.85H2O: C, 50.94; H, 4.71; N, 9.90; found: C, 50.61; H, 
4.68; N, 9.74. 
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2,5-Bis[2-iso-butoxyl-4-(4-1H-imidazylimino)aminophenyl]furan.HCl (11). 
11 was synthesized by following a similar procedure to that used for the synthesis of 7, starting 
with 42 and resulted in a orange  solid (56%), mp: 235-237 oC. 1H NMR (MeOD): δ 8.48 (s, 
2H), 8.36 (s, 2H), 8.19 (d, 8.0 Hz, 2H), 7.24-7.18 (m, 6H),  4.04 (d, J=4.0 Hz, 4H), 2.34-2.28 
(m, 2H), 1.18 (d, J=6.8 Hz, 6H);   13C NMR (MeOD): δ 157.5, 156.6, 149.8, 139.2, 134.6, 
128.1, 127.8, 124.7, 121.3, 118.4, 114.5, 110.5, 76.7, 29.6, 18.8; ESI-MS: m/z calculated for 
C32H36N8O3: 580.3; found: 581.3 (M+1). Analysis calculated for C32H36N8O3-4HCl-1.5H2O-
0.5C4H10O: C, 51.65; H, 6.11; N, 14.17; found: C, 51.84; H, 5.89; N, 14.17. 
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Synthesis and Evaluation of Dual Wavelength Fluorescent Benzo[b]thiophene Boronic 
Acid Derivatives for Sugar Sensing 
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Design and Synthesis of Linear Diamidine Molecules as Antiparasitic Agents 
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Synthesis of Arylimidamides as Potential Leishmanisis Treatment Agents 
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